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Our fascination with what 
constitutes mental health 
(and its opposite) is as old as 
humankind. From the paintings 
in the Chauvet cave in southern 
France that merge animal with 
human images to discussions 
of biological versus cultural 
behavior in Plato’s Phaedrus, 
and onward to Freud and Frankl, 
humans have questioned the 
meaning of healthy and sick, of 
consciousness and of consci-
entiousness. It has been neither 
an easy path nor a short one, 
but exciting new research may 
signal that physical answers are 
at hand.
In today’s world, people are 
more broadly aware of the dif-
ference between wellness and 
mental illness—and science 
has opened up impressive new 
opportunities to help people live 
more comfortable and produc-
tive lives. These developments 
have led to a widened definition 
of mental illness. And as the 
definition of mental illness has 
expanded along with opportu-
nities to heal or cure formerly 
treatment-resistant conditions, 
the definition of mental health 
has contracted but become more 
precise. People know what men-
tal well-being is, and are increas-
ingly able to expect good health, 
whether it comes through nature, 
education, or medicine.
Advances in the neurosci-
ences have brought a clearer 
view of what trauma can do to 
a brain, for instance. These new 
insights include the fact that 
some individuals can absorb 
more damage than others  
(psychological resilience as well 
as physical ability to absorb 
concussions), and how that 
difference shapes what had 
been viewed as immutable per-
sonality traits, like susceptibil-
ity to depression and anxiety. 
Once considered a behavioral 
problem, the symptoms of 
traumatic psychiatric injury 
have been demonstrated to 
be both physical and treatable. 
Trauma and mental illness are 
now treated less as a source 
of shame (as they once were) 
and more like problems to be 
resolved through the attention 
and ministration of experts. 
Even schizophrenia, recently 
seen as a kind of life sentence, 
is treatable, especially if diag-
nosed early. 
This issue highlights the 
ongoing work of some of Yale’s 
leading scientists in the fields 
of neuroscience and psychiatry. 
Nevertheless, with so many 
exceptional achievements accu-
mulating in laboratories and 
clinics around the university, it 
is impossible to describe all of 
them. That is often the case 
with magazines like this, and I 
encourage readers who have 
knowledge of other research 
and researchers to reach out to 
us via email or letter. We wel-
come correspondence and enjoy 
sharing your recollections with 
others, both online and offline.
Adrian Bonenberger 
Editor, Yale Medicine Magazine
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  The changing  
world of mental health
the science behind mental health has long been one of Yale’s 
strengths. Robert J. Alpern, MD, dean and Ensign Professor of 
Medicine, talks about the direction of the field today and why society 
ought to do a better job of taking mental health issues seriously.
What are the key challenges facing people who need mental health treatment?  
Mental health care has changed significantly since I entered medicine. Patients 
with significant mental health disorders were hospitalized for lengthy stays and 
the public probably envisioned those stays as being something like that described 
by Ken Kesey in the 1962 novel One Flew Over the Cuckoo’s Nest. Now, most are 
treated as outpatients and there’s more emphasis on medication, with less empha-
sis on psychotherapy.
What changed? In the past, mental health was viewed as a problem on the periphery 
of medicine that most physicians could not fully comprehend and wanted to avoid.  
An understanding of the neuroscience wasn’t really there for drug development, nor 
was the technology sophisticated enough to image or treat chemical imbalances or 
physical trauma. We now realize that mental health is central to overall wellness. 
Mental health is a major concern for this country and the world. We don’t treat it well 
at all and I think we’re all aware of that now. We need to make meaningful changes.
Is there anything we can do to fix the system? The entire system is underfunded,  
to begin with, but the cost that it would take to really treat mental health disorders 
as they should be treated would be very large. Still, the costs to society of not  
treating these conditions have been and will continue to be enormous. The question 
of how serious we want to be about treating mental health is one of the great  
challenges we face as a country.
Does technology hold any hope for improved accessibility or treatment? The short 
answer is yes. The longer answer is that technology is always advancing, and  
the tools we’ve needed to diagnose underlying biological or chemical causes of  
mental health disorders are still being developed. Here at Yale we have an out-
standing neuroscience program, an outstanding psychiatry department, and an 
outstanding neuroscience imaging program. I’m confident that our researchers  
will be playing a major role in making quality psychiatric care more available.
Will mental health be a right some day? It’s hard to say that mental health is or will be a 
right. But I think it’s a right to have access to the best mental health treatment. We need 




   New stem-cell  
 cultivation procedure  
  boosts hope for cures
when the taylor lab in Yale’s Division of Reproductive 
Sciences extracted stem cells from human endometrial 
tissue—more commonly known as the uterine lining— 
the researchers were proud of their accomplishment. 
They didn’t think the find was extraordinary, and they 
certainly didn’t imagine that it might lead to treatments 
for a neurodegenerative condition. They were wrong—
and happily so.
“The best discoveries through-
out the history of science have 
not been predictable, have not 
always come out the way we 
anticipated they would, or the 
way we designed them to,” says 
Hugh Taylor, MD, HS ’92, FW ’98, 
chair and the Anita O’Keeffe 
Young Professor of Obstetrics, 
Gynecology, and Reproductive 
Sciences, and professor of molec-
ular, cellular, and developmental 
biology. “That’s the real excite-
ment in science—when it doesn’t 
follow the predicted path, when 
you get a surprise.”
The surprise, in this case, 
wasn’t finding the multipo-
tent stem cells but finding 
their proclivity to differentiate 
into dopaminergic neurons: 
the brain cells whose loss in 
Parkinson’s disease leads to 
tremor, speech difficulty, poor 
balance, and a host of other 
symptoms. A reproductive sci-
ences laboratory like Taylor’s  
is not where one would 
expect to find a treatment for 
Parkinson’s disease. 
“There certainly aren’t dopa-
minergic neurons in the uterus,” 
Taylor says. 
Though unintended, the 
discovery has been serendipi-
tous and is unfolding quickly; 
so far, the team has demon-
strated the neurons’ ability to 
boost fallen dopamine levels 
in mouse and primate models 
of mild Parkinson’s disease. In 
future studies, the team hopes 
to examine more severe forms 
of the disease to identify the 
therapy’s effects on physical 
symptoms beyond improving 
dopamine levels. 
The stem cells’ tendency to 
differentiate into dopaminergic 
neurons is as yet unexplained, but 
Taylor and his colleagues have 
also coaxed the cells into becom-
ing insulin-producing beta cells. 
Trials in mouse models have used 
endometrial stem cells to produce 
beta cells that continued produc-
ing insulin and stabilized blood-
glucose levels within five weeks 
when injected into diabetic mice.
Taylor credits the cascading 
discoveries not only to his team 
and colleagues in other depart-
ments but to the collaborative 
atmosphere that facilitates the 
researchers’ interactions.  
“For each of these applications  
[of endometrial stem cells],  
we found the world’s expert  
right in our backyard,” he says.  
“You have world-leading experts 
in these diseases right down 
the hall, or in the building 
across the street, who are more 
than glad to help advance col-
leagues’ research as collabora-
tors.” It helps that stem cells are 
a valuable currency across all of 
medicine because of their unique 
ability to produce myriad differ-
ent cell types—when given the 
right environment. The endome-
trium, regenerating month  




to obtain additional stem cells. 
These could then be used to treat 
people without a uterus. 
“There are tremendous appli-
cations in almost all fields of 
medicine. I think the sky’s  
the limit, really,” Taylor said. 
“Any disease where cells become 
defective or die, we can con-
sider using stem cells to replace 
them.” Parkinson’s disease  
and diabetes are only two of 
thousands of medical condi-
tions that could one day be 
treated—or cured—with cell-
based therapies. 
“Stem cell research has shown 
potency; it has tremendous 
potential,” Taylor said. “I think 
that cell-based therapy can do 
things that drugs could never  
do, and I think we’ll see a lot 




Vectors: An insect varia-
tion on viral visitations
Few scientists view the immune 
system as a binary between 
human and nonhuman infection. 
In many cases—dozens known 
for certain to science, and likely 
thousands or millions given the 
variety of life forms in animal 
bodies—bacteria and viruses have 
evolved along with more compli-
cated organisms, becoming inex-
tricably linked to health. It may 
not be accurate to describe these 
ancient intruders as separable 
from a “healthy” body—although, 
strictly speaking, they are unde-
niably infections.
The human immune system 
and its bacterial allies aren’t the 
While adult stem cells reside 
in many different tissues, find-
ing and extracting them in great 
numbers is challenging and—in 
all instances but one—invasive. 
The endometrium is the only tis-
sue from which adult stem cells 
can be retrieved via a routine 
office-based procedure without 
anesthetic. This source is not 
limited to women of reproduc-
tive age, either: estrogen treat-
ment can stimulate endometrial 
growth in women of all ages. 
Treatments that use a patient’s 
own cells are attractive because 
they eliminate the risk of tissue 
rejection. Taylor envisions tissue 
banks that would use material 
retrieved from hysterectomies 
Hugh Taylor hopes that 
the new procedure for 
sustainably harvesting 
stem cells will lead to 
extraordinary new  
developments in person-
alized medicine, and  
aid in further medical 




















based on the methods 
of William Steward Hal-
sted have long been the 
gold standard for aspir-
ing surgeons. They’ve 
also been very hard on 
the physicians who go 
through them, and the 
idea of single-minded 
devotion to craft may 
have contributed to 
physician burnout and 
addiction later on in life. 
Current surgical faculty 
at YSM are pushing to 
change how surgical 
residencies function … 
for the better. 
For more on surgical  
residencies, visit ymm.
yale.edu/surgicalres
is also the case with mosquitoes 
in India. Many factors, intrinsic 
and extrinsic, influence infec-
tion prevalence—this is complex. 
We wanted to examine whether 
the tick gut microbiome might 
represent one factor, and if 
shifts in the tick’s microbiome 
might contribute to the tick’s 
ability to host and transmit  
the pathogens.”
Research conducted by sev-
eral groups into the lives of 
African mosquitoes suggests 
that mosquitoes’ gut micro-
biota influence the survival of 
their malaria-causing parasites. 
Articles published in the last 
decade uncovered correlations 
between bacteria present in 
arthropods like Aedes aegypti 
and resistance to such deadly 
pathogens as (in the case of 
Aedes aegypti) the dengue virus.
Narasimhan and Fikrig’s 
efforts indicate that the microbi-
ome of ticks does play some role 
in ticks’ “health” in the context of 
how they acquire pathogens and 
how they molt, but the research-
ers are still working to establish 
the precise nature of that role, as 
well as which microbiota or sub-
set of microbiota observed in ticks 
might play a significant role.
Ultimately, Fikrig and 
Narasimhan hope that if we 
understand how the tick micro-
biome influences tick-borne 
pathogens, it may be possible to 
leverage that knowledge to reduce 
the prevalence (if not the viru-
lence) of tick-borne diseases.
Serap Aksoy, PhD, FW ’88, 
professor of epidemiology 
only line of defense against hos-
tile diseases, though. As scien-
tists reevaluate what constitutes 
immunity on an individual level, 
the health of vectors, the means 
by which hostile viruses and 
bacteria are transmitted into 
human bodies, has taken on a 
new significance. 
“A vector is an organism that 
serves as a necessary intermedi-
ary for human disease, or other 
animal diseases,” says Leonard 
Munstermann, PhD, a senior 
research scientist in epidemiol-
ogy (microbial diseases) at the 
Yale School of Public Health. 
Munstermann focuses on 
population genetics and taxo-
nomic relationships among the 
400 species of South American 
phlebotomine sand flies, some 
of which are responsible for 
spreading leishmaniasis. 
Past efforts to control vectors 
have included wildly destruc-
tive assaults on the environment. 
Alongside developing medical 
technology, ecological awareness 
has led to other ways to affect 
vectors. Most recently these 
include attempts to strengthen 
their immune systems against 
infection. Researchers hope to 
preserve animals and microbes 
that may be crucial to the food 
chain in some manner that isn’t 
understood today while remov-
ing the threat that they pose to 
human populations.
“Especially for the parasitic 
protozoans, which have few 
convenient antibiotic cures, 
targeting the vectors them-
selves is a promising route for 
researchers,” says Munstermann. 
“Sand flies, mosquitos like the 
dreaded Asian Tiger Aedes 
albopictus, ticks, tsetse flies, 
and other arthropods harbor 
within them a host of debilitat-
ing diseases that are anathema 
to human health.”
A longtime source of illness 
and debilitation for humans, ticks 
are a vector that has rebounded 
as New England farmland has 
receded and forests have regrown. 
Sukanya Narasimhan, PhD, 
FW ’93, a senior research scien-
tist in the Section of Infectious 
Diseases, studies the microbiome 
of the deer tick in collaboration 
with Erol Fikrig, MD, FW ’92, the 
Waldemar von Zedtwitz Professor 
of Medicine (Infectious Diseases), 
professor of epidemiology (micro-
bial diseases), of microbial patho-
genesis, and chief of the Section of 
Infectious Diseases. Together the 
two researchers hope to identify 
ways to reduce the tick’s ability  
to host pathogens that are dan-
gerous to humans and human-
adjacent animals. 
Narasimhan says that as evi-
dence mounted about the mam-
malian microbiomes and their 
impact on human health, “We 
wondered if ticks might harbor 
microbiota, and if their indig-
enous bacteria affect the tick, 
how it acquires pathogens, and 
how it passes them on to us.”
She adds, “Tick prevalence 
doesn’t necessarily mean infec-
tion prevalence, so there could 
be parts of the United States 
where you have a lot of ticks, but 




Turning the page:  
The transformation of 
the Medical Library
When John Gallagher, the direc-
tor of the Cushing/Whitney 
Medical Library (CWML), arrived 
at Yale nearly two decades ago, 
the bustling information hub of 
Yale School of Medicine actively 
received 2,600 individual scien-
tific journal titles in print format. 
The newest journal issues were 
shelved in the Morse Reading 
Room, while older issues, bound 
in volumes, occupied entire floors 
of space in the journal stacks on 
the basement level. Researchers 
photocopied articles and library 
staff reshelved thousands of 
bound volumes each week. 
But there was a digital revolu-
tion in the offing: within five 
years, that list of 2,600 titles had 
dwindled to around 100. It has 
continued to drop; these days, 
the library receives just a handful 
of print journals. Students and 
microbes, the Wigglesworthia 
species (named after the famous 
British entomologist who first 
described it) shares an obligate 
association with its tsetse host. 
Without Wigglesworthia,  
which produces essential nutri-
ents missing from tsetses’  
vertebrate blood specific diet, 
adult flies present a severely 
compromised immune system 
and are reproductively sterile. 
This research provides useful 
insights for developing control 
strategies aimed at reducing  
tsetse population size and/or 
inhibiting the fly’s ability to 
transmit trypanosomes. 
Tsetse flies house other 
symbiotic bacteria that may 
also reduce disease transmis-
sion. “Most tsetse flies harbor a 
commensal bacterium from the 
genus Sodalis (which means 
‘companion’ in Latin) that, simi-
lar to Wigglesworthia, is passed 
from mother to larva via milk. 
This bacterium can live outside 
of its host and be genetically 
modified. If we can customize 
Sodalis to produce a trypano-
cidal protein, and then return 
these bacteria to the fly, they 
may become more resistant to 
infection,” says Aksoy. These 
characteristics make Sodalis an 
attractive target for research.
“We’ve designated insects 
that carry genetically modified 
symbionts as ‘paratransgenic,’ ” 
says Aksoy. “And one of these 
days, they might help wipe out 
some of humanity’s most pro-
lific killers.”
—Adrian Bonenberger
(microbial diseases) in the Yale 
School of Public Health, has 
battled the protozoan parasites 
that cause African trypanoso-
miasis (more commonly known 
as “African sleeping sickness,” 
which is fatal if untreated) for 
decades. Her research into the 
insect vector primarily respon-
sible for spreading the disease— 
the tsetse fly—has resulted in 
numerous breakthroughs: most 
recently, a mechanism that 
reduces the fly’s ability to transmit 
disease-causing trypanosomes.
“One of the more interest-
ing characteristics of the tsetse 
fly is its mode of reproduction,” 
says Brian Weiss, PhD, FW ’08, 
research scientist and lecturer 
in epidemiology (microbial dis-
eases) in the School of Public 
Health. Weiss, who works in 
Aksoy’s lab, knows a great deal 
about the topic. “Tsetse flies 
reproduce through a process 
called adenotrophic vivipar-
ity, which means gland-fed live 
birth. In this situation, embry-
onic and larval stages (one 
per reproductive cycle) occur 
within the mom’s uterus, and 
the larva receives nourishment 
in the form of milk secreted by 
a modified accessory gland.” In 
contrast, almost all other female 
insects will lay a clutch of fertil-
ized eggs into their environment 
and hope that a couple of them 
reach sexual maturity.”
Aksoy and her research team 
discovered that tsetse milk also 
contains symbiotic bacteria that 
mediate numerous aspects of the 
fly’s physiology. One of these 
Part of the effort to 
stop diseases involves 
protecting humans 
from infection. Rather 
than killing vectors 
with such ecologically 
harmful procedures 
as spraying against 
mosquitoes or ticks, 
another approach re-
searched in places like 
Yale involves protect-
ing those insects from 














A recent graduate 
of Yale is working on 
blended and augment-
ed reality technology 
in cooperation with 
YSM faculty, that could 
revolutionize how 
patients with problems 
seeing (such as the 
blind) interact with 
their surroundings.
For more on blended 
and augmented reality 
technology, visit ymm.
yale.edu/blendedreality
researchers, however, have never 
had greater access to biomedical 
literature, as they now have digi-
tal access to some 23,000 library-
licensed journals. The fact that 
these journals take up virtually 
no room has been a game-changer 
for CWML and YSM.
“The transition from print to 
electronic has freed up an enor-
mous amount of space, and it’s 
given us a chance to think about 
the best way to use it,” says 
Gallagher. “This has been a great 
opportunity and we’re really 
excited about it.”
The library teamed with 
Richard Belitsky, MD, HS ’82, 
FW ’83, the Harold W. Jockers 
Associate Professor of Medical 
Education and deputy dean for 
education; Michael Schwartz, 
PhD, associate dean for curricu-
lum and associate professor of 
neuroscience; and other admin-
istrators at the medical school to 
come up with an innovative proj-
ect that marries the library’s core 
mission as a center of learning 
with ongoing curriculum reform.
Signs bearing the image 
of “Hard Hat Harvey” Cushing 
began appearing in the library’s 
halls and on its website last 
summer. Since then, the quiet 
is sometimes broken during 
the day by Petra Construction 
Corporation workers tasked 
with gutting and transforming 
much-used and now cordoned-
off areas of the first floor, base-
ment, and sub-basement. (Many 
sections of CWML, such as the 
Morse Reading Room and the 
Historical Library, are not part 
of the renovation.) When the last 
literal hard hats finish up work in 
June 2019, the reengineered space 
will be home to a team-learning 
classroom that can accommodate 
120 students; eight smaller class-
rooms; a quartet of group-study 
rooms; and an information com-
mons equipped with 30 com-
puter workstations, a faculty 
video-production studio, and the 
offices of several librarians. 
“Our students come from an 
era in which they have rapid 
access to information, a high 
reliance on technology, and an 
emphasis on interactive learn-
ing,” says Belitsky, “and the 
curriculum we implemented in 
2015 is designed to reflect that. 
But if you change your pedagogy, 
you need different spaces that 
can better carry out these new 
ways of teaching.”
The old model—the learned 
professor standing at a lectern 
and dispensing wisdom to aco-
lytes frantically scribbling down 
every fact—has been set aside 
in favor of the “flipped curricu-
lum” model. This model requires 
a team-learning classroom in 
which students gather around 
tables in groups of about a half 
dozen. Medical students will  
have already read and mastered 
an assignment or absorbed a  
professor-created video, and 
they’ll come to class to work with 
their peers on projects overseen  
by their teacher, to implement 
what they’ve learned, and to share 
and debate their ideas in real time.
“Medicine today is a 
team-based endeavor,” notes 
Schwartz. “Our new curriculum 
reflects this reality, and the new 
classroom gives us an effective 
space for helping our students 
develop the perspective and 
expertise to work this way. 
Learning is less about facts and 
more about the process of evalu-
ating and applying information, 
so it makes a lot of sense to cen-
ter this in the library.”
The renovated spaces also 
are designed to better imple-
ment a team-based interactive 
approach, and the planners were 
mindful of crafting a facility 
that would be flexible and useful 
to the wider School of Medicine 
community after the students 
leave the rooms. “The challenge 
was adopting the area for teach-
ing while at the same time pre-
serving the history and charm of 
the library,” says Schwartz.
The result will be a suite of 
places that can serve as both 
classrooms and after-class spots 
for study; such community edu-
cation opportunities as lectures 
and seminars; and social gather-
ings. The library still acquires and 
shelves books and remains home 
to one of the world’s most impres-
sive medical-historical collections. 
“When this is done, we’ll be able to 
connect people with information in 
ever more sophisticated and effec-
tive ways,” explains the Medical 
Library’s associate director, Holly 
Grossetta Nardini, “and we’ll pre-
serve the kind of serendipity that 
often results when people interact.”





People have long understood that hav-
ing a suicide in one’s family elevates other 
members’ risk of suicide in ways that 
haven’t always been tangible or under-
stood. Now, scientists at Yale, including 
Joel Gelernter, MD, the Foundations Fund 
Professor of Psychiatry and professor of 
genetics and of neuroscience, and Daniel 
Levey, PhD, have identified genes linked to 
suicide attempts in different U.S. popula-
tions. They hope to broaden the investiga-
tion by evaluating data collected through 
the Department of Veterans Affairs’ 
Million Veterans Program (MVP). The 
suicide rate among veterans has grown in 
recent years, and reducing it is a priority 
for health care administrators.
At the University of Minnesota in 1911, phys-
icist John Zeleny, who also worked at Yale 
during World War I, developed an appara-
tus called “electrospray” to study electrical 
discharge in gases. Electrospray involves 
driving fluid through a tiny aperture; the 
resulting mist can then be evaluated at the 
molecular level. Alessandro Gomez, PhD, 
and Juan de la Mora, PhD, both professors 
of mechanical engineering and materials 
science, continue this line of inquiry. One 
successful collaboration involved working 
with the lab of Tarek Fahmy, PhD, associate 
professor of biomedical engineering and 
immunobiology, to synthesize nanopar-
ticles for the delivery of cancer drugs.
The Department of Emergency Medicine 
at Yale School of Medicine is working on 
a project designed to serve a tradition-
ally underserved and systematically 
exploited population: the elderly. One in 
10 Americans over the age of 60 is mis-
treated in some way, and VOICES (Virtual 
cOaching in making Informed Choices 
on Elder mistreatment Self-disclosure), 
funded by a $1.5 million grant from the 
National Institute on Aging, will help vic-
tims report physical, emotional, financial, 
or sexual abuse and seek assistance.
GIVING THE ELDERLY  
THEIR VOICES BACK 
SUICIDE RISK IN THE GENOME 
ELECTROSPRAY INNOVATION 
DRIVES SCIENTIFIC ADVANCES 
As scientists investigate the human 
microbiome, efforts are underway to 
step back and understand how various 
human microbiomes affect each other 
during face-to-face social interactions. 
Led by Nicholas Christakis, MD, MPH, 
PhD, Sterling Professor of Sociology, and 
funded by a $3.54 million grant from the 
NOMIS Foundation, the Microbiome 
Biology and Social Networks in the 
Developing World project will gauge how 
our friends’ and relatives’ health affects 
our own—on a bacterial level. When Mom 
said, “Wash your hands before dinner,” 
she wasn’t saying it just for your own 
good, but for hers too!
IN-PERSON SOCIAL NETWORKS 
AFFECT THE MICROBIOME 
9Spring 2019













TH E THIR D EDITIO N of the Diagnostic and Statistical Manual of Mental Disorders, 
published in 1980, was the first to describe psychopathy as antisocial personality disor-
der (or APD/ASPD). This diagnosis depended on decades of studies, professional conver-
sations, and advances in neuroscience and technology. Eventually, scientists determined 
that the condition is neither a moral failing nor (for the most part) a failing of society, 
but rather the result of a combination of genetic and social influences. Since 1980, the 
standard by which professional physicians judge whether someone is a psychopath has 
expanded but not changed fundamentally. Meanwhile, researchers have inched closer to 
understanding the underlying causes of mental disorders in people previously described 
as “crazy” … and how to treat those causes.
An evolving idea of what drives mental illness informs mental wellness. And a great 
many advances in that field are unfolding at Yale School of Medicine. Phil Corlett, PhD, 
FW ’10, and Albert Powers, MD, PhD, HS ’16, use research with psychics to better un-
derstand the root causes of hallucinations common in schizophrenia. Lynnette Averill, 
PhD, FW ’15, is involved in trials overseeing the prescription of ketamine to heal patients 
suffering from post-traumatic stress disorder, expanding on pioneering research con-
ducted by John Krystal, MD ’84. Emma Lo, MD, a fourth-year resident in the department 
of psychiatry, takes this research and applies it on the clinical level to a population that 
disproportionately suffers from mental illness, people experiencing homelessness.
These stories and more examine experts’ role in triangulating the causes of diseas-
es and genetic conditions. Resolving biological mysteries is at the heart of contempo-
rary mental health research. So much of what’s exciting in the field involves technologi-
cal advances at Yale that pose new questions and answer old ones.
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A look at the state of mental health and its inverse, 
mental illness, from prominent Yale School of 
Medicine faculty and researchers from the depart-
ments of psychiatry and neuroscience. 
Albert Rivera has had a hard-luck life. As a child, he 
experienced physical and emotional abuse. Now 38 
years old and living in New Haven, he suffers from 
post-traumatic stress disorder (PTSD) and is in recov-
ery from alcohol and opioid abuse. To top things off, 
he’s in transitional housing—without a dependable roof 
over his head.
Yet Rivera has hope for his future. He holds a job and 
he stays on an even keel by participating in two programs 
run by Yale School of Medicine. One helps people with 
mental illnesses deal with the stresses of life, and the 
other enables them to play positive roles in the community. 
“They help me cope,” Rivera says. “They gave me a purpose 
and made me part of something bigger than myself.” 
The programs are examples of an emerging trend 
in the treatment of mental illnesses called recovery-
oriented care and citizenship. The idea is that helping 
people cope with their illnesses and live productive 
lives as valued members of their communities is an 
essential part of their care—alongside medications, 
talk therapy, and other treatments. 
Recovery-oriented care and citizenship are part of 
a major rethinking of mental illness and care that is 
now underway nationwide. Until recently, the pri-
mary focus among mental health professionals has 
been on identifying therapies that suppress the symp-
toms of disease and administering those therapies  
in a clinical setting. Increasingly, though, research-
ers are focusing on understanding the core causes 
and mechanisms of mental illness, and clinicians are 
helping their patients grapple with the social deter-
minants of health while developing a sense of belong-
ing in their communities. 
In a sense, mental health care is being redefined—
becoming ever more precise and personalized in 
the biological research sphere and more holistic and 
patient-centric in the way treatment is provided.  
“We need to think differently about psychiatry than we 
have in the past,” says John Krystal, MD ’84, HS ’88, 
the Robert L. McNeil, Jr. Professor of Translational 
Research, professor of psychiatry and of neuroscience, 
chair of the Department of Psychiatry at Yale School of 
Medicine, and chief of psychiatry at Yale New Haven 
Hospital. He believes the department will play a sig-
nificant role in advancing science, improving care, and 
training the next generation of leaders in the field.
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Progress is sorely needed. That’s because the state 
of mental health in the United States is poor. Nearly 
20 percent of the population, or about 60 million people, 
suffer from some type of mental illness each year. More 
than 24 million people struggle with substance abuse. 
The treatment of mental illness has undergone 
waves of change over the past 100 years. The field was 
defined in the early- to mid-20th century by mass 
institutionalization, poorly informed use of lobotomies, 
and the dominance of psychoanalysis. Over time, those 
approaches gave way to deinstitutionalization, rapid 
proliferation of drug treatments, cognitive behavior 
therapies, and now psychosocial interventions, includ-
ing recovery-oriented care. 
Understanding of the causes of mental illness has 
evolved as well. Psychiatry pioneer Sigmund Freud 
posited that mental illness is caused by conflicts 
between different parts of the mind resulting from 
childhood trauma. Later, leaders in the field came to 
believe that mental illness is the result of disruptions 
in biological processes. Now psychiatrists increas-
ingly recognize the powerful impacts poverty and 
other traumatic life experiences have on mental health. 
“Each view has enriched the picture. They complement 
each other in explaining mental illness and foster-
ing new treatment directions,” says Michael Sernyak 
Jr., MD, HS ’91, professor of psychiatry and CEO of 
Connecticut Mental Health Center (CMHC).
Yale has long been recognized as a national leader in 
psychiatry. Today its psychiatry department is one of 
the largest in the country, with more than 350 faculty 
members. Yale’s partnership with the VA Connecticut 
Healthcare System has produced numerous advances in 
PTSD treatment. Its joint venture with the state in CMHC 
provides psychiatric care for more than 5,000 economi-
cally disadvantaged people each year. Yale Child Study 
Center is renowned for research and clinical care. And 
the Interventional Psychiatry Service at Yale New Haven 
Psychiatric Hospital is a leader in providing people with 
severe mental illness with access to the latest experimen-
tal treatments. 
new directions in the biology of mental illness
Breakthroughs in understanding human biology in the 
mid-20th century led to the development of medications 
for mood disorders and psychosis—alleviating suffering 
for millions of people. Yet most of the “wonder drugs” 
introduced during that era addressed the symptoms 
rather than the causes of disorders.
A new wave of biological research spanning neuro-
science and genetics is deepening our understanding 
of mental illness’s underlying biology. This research 
promises to deliver a new generation of medications 
and treatments that target causes. “This is opening up 
a whole host of new treatment options,” says Gerard 
Sanacora, MD, PhD, HS ’98, FW ’99, the George D. and 
Esther S. Gross Professor of Psychiatry and director of 
the Yale Depression Research Program.
One of the major breakthroughs in this area came 
in the 1990s when Krystal and colleagues discovered 
that the drug ketamine, an anesthetic, could provide a 
fast-acting treatment for depression. Previously, anti-
depressants had focused on suppressing unruly chemi-
cals in the primitive parts of the brain. But ketamine 
targets the chemical glutamate in the neocortex, where 
memory and thought reside. The drug treats a cause 
rather than a symptom. The hospital now offers experi-
mental ketamine infusion therapy for depression.
These days, research labs within the School of 
Medicine are using neuroimaging and genetics to probe 
deeper into the workings of the brain. One lab, run 
by Ronald Duman, PhD, FW ’88, the Elizabeth Mears 
and House Jameson Professor of Psychiatry, professor 
of neuroscience, and director of the Abraham Ribicoff 
Research Facilities at CMHC, has been studying ketamine 
to better understand the pathophysiology of depression. 
His team discovered that for some individuals, chronic 
stress and depression cause atrophy and loss of synapses, 
reducing connectivity in the brain. Ketamine promotes 
the growth and vitality of synapses. “We’re learning 
more about how the brain works,” says Duman.
One of the team’s primary goals is to discover 
alternative therapies to ketamine that don’t carry the 
drug’s negative side effects, such as hallucinations.
As researchers probe the brain, they’re making discov-
eries that may lead to a reclassification of mental illnesses. 
Today, psychiatrists refer to the Diagnostic and Statistical 
Manual of Mental Disorders, fifth edition (DSM-5) to 
make their diagnoses. Its classifications of disorders are 
based primarily on observations of behavior. Increasingly, 
  Michael Schwartz
 “Things come in organically by virtue  
   of the fact that our faculty  
  are world leaders in their fields. 
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researchers find that the phenomena they observe in the 
brain do not line up with DSM diagnoses. There’s too much 
overlap to separate these phenomena into strict categories. 
As research advances, it may turn out that many illnesses 
have the same causes, such as stress and inflammation—
leading to new treatment strategies.
Because of the ever-increasing role of neurosci-
ence in psychiatry, the Department of Psychiatry’s 
residency program has evolved to include training in 
applying neuroscience to clinical practice. “The goal 
is to help clinicians arrive at more accurate diagnoses 
and to communicate better with patients about what’s 
going on,” says David Ross, MD ’05, PhD ’04, associate 
professor of psychiatry, who led the initiative.
Rather than relying on traditional lectures, the 
curriculum includes videos, interactive exercises, and 
resources for self-directed study. 
Ross, working with colleagues at Columbia 
University and the University of Pittsburgh,  discov-
ered that few residency programs around the country 
were incorporating neuroscience into how they taught 
psychiatry. To address that gap, Ross’ group cre-
ated the National Neuroscience Curriculum Initiative 
(NNCI), which offers a comprehensive set of teach-
ing and learning resources, many of which were first 
implemented at Yale. Today, more than 100 residency 
programs use the curriculum, and the website has 
36,000 registered users from 153 countries.
helping patients live in the world
In 1977, two women in Madison, Wis., Harriet Shetler and 
Beverly Young, met for lunch to discuss the challenges 
faced by their sons, who had been diagnosed with schizo-
phrenia. That fateful meeting marked the beginning of the 
mental-health patients’ advocacy movement, which has 
pushed the psychiatric community to provide care that 
respects patients’ rights and wishes. Out of that shift in 
perspective came recovery-oriented care.
The core idea is that people with mental illness can 
recover even though they’re not “cured.” They can live 
satisfying lives—holding jobs, enjoying their families, 
and contributing to society. “These interventions are 
aimed at the recovery of daily function and life. The 
focus is on helping a person have the kind of life they 
want,” says Larry Davidson, PhD, FW ’92, profes-
sor of psychiatry and director of the Yale Program for 
Recovery and Community Health (PRCH).
His organization does research, training, and policy 
development aimed at equipping health care and social 
service agencies to support recovery-oriented care.  
It also runs experimental programs in New Haven that 
provide direct support for patients—including person-
centered care planning and community-based recov-
ery programs. 
The ultimate goal of recovery-oriented care is achiev-
ing wellness—improving mental and physical health by 
expanding awareness and making better choices in all 
  Chyrell Bellamy
 “We need leaders with lived experience  
at the table so that we can together  
  transform health care organizations. 
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dimensions of life. Wellness is not the absence of illness 
or stress; it’s making the best of one’s situation. 
Citizenship adds another dimension, recognizing 
the rights, responsibilities, roles, resources, and rela-
tionships necessary for contributing to community on 
one’s own terms, often through involvement in collec-
tive endeavors.
A lot of the work being done at PRCH is practical 
and utilitarian. The programs help people get jobs and 
diplomas. CMHC, for instance, provides bicycles for 
some of its low-income patients, enabling them to get 
to appointments and jobs on time, and improving their 
physical fitness and self-esteem.
There’s also a strong emphasis on heeding the 
wishes of the patient. For instance, a person may 
choose to forgo a medication that suppresses their 
symptoms because it also makes them groggy, inter-
fering with their ability to work and socialize.
A key element in such programs is the role of peers—
individuals who have experienced mental illness and/
or substance abuse who advise and guide patients as 
they navigate their recovery. A peer-support staff 
member in New Haven, Richard Youins, helps run a 
weekly discussion group at CMHC and coordinates 
Magicians Without Borders, which teaches people 
magic tricks they can use as icebreakers when they  
tell their stories in public. “When I was in addiction,  
if somebody had told me I would someday have  
a job where I was doing good things for other people,  
I would have laughed. But it happened,” he says. 
“We’re all walking, breathing possibilities.”
Studies of the PRCH programs have shown that peer 
support reduced hospital readmissions by 42 percent, 
reduced hospital stays by 48 percent, and improved 
relationships with health care providers.
The School of Medicine is also helping people in 
recovery play roles in reforming the mental health care 
system. Lived Experience Transformational Leadership 
Academy, a nine-month training program, prepares 
people to develop and enhance their capacity for 
leadership. “We need leaders with lived experience 
at the table so that we can together transform health 
care organizations,” says Chyrell Bellamy, PhD, MSW, 
associate professor of psychiatry and director of Peer 
Services and Research at PRCH.
In order to equip future psychiatrists to provide 
recovery-oriented care, the Department of Psychiatry 
has developed a robust social justice and health equity 
program within the residency curriculum. “We can 
predict more about a person’s health from their ZIP 
code than their genetic code, so we need to train resi-
dents about implicit bias and the roles of communities 
in mental health,” says Robert Rohrbaugh, MD ’82, 
HS ’86, FW ’88, professor of psychiatry and deputy 
chair for Education and Career Development.
The social justice and health equity program takes res-
idents out of the classroom and clinic into New Haven’s 
neighborhoods, where they learn how such factors as 
housing, employment, transportation, and neighborhood 
gardens can be barriers to health or help improve it.
For Hana Ali, MD, a second-year resident, the pro-
gram was a revelation. A guided tour last year of the 
New Haven neighborhood where she lived took her 
under the surface to understand the experiences of her 
neighbors. “It told me there are lived experiences of 
the patient we take care of that we have no idea about. 
In order to care for a person, you need to get a full 
sense of them—what their lives are like,” she says.
Along both vectors where mental illness is being 
rethought, the biological and the behavioral, research-
ers and clinicians are gaining knowledge rapidly.  
“It is wonderfully stimulating to work in a community 
where the issues arising from basic science, the  
clinic, and the community converge,” says Krystal.
Huge challenges remain. The mechanisms of the 
brain are amazingly complex and difficult to interpret. 
The interactions of individuals with others and society 
are so varied. There are many stressors in modern life.
Yet School of Medicine faculty members are 
optimistic that new scientific discoveries and new 
approaches to treatment will improve the lives of those 
who suffer from mental illnesses. “We’ll have break-
throughs. It’s what we are as a species,” says William 
Sledge, MD, HS ’75, the George D. and Esther S. Gross 
Professor of Psychiatry Emeritus, who was for many 
years the medical director of psychiatry at the hospital. 
“We will find a way.” /yale medicine magazine
Steve Hamm is a frequent contributor to Yale Medicine Magazine.
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Armoring the psyche:  
A brain’s resilience 
Studies indicate that people whose brains are  
“wired” for resilience can also receive training that  
further fortifies them against psychiatric trauma.
By John Altavilla
What makes one human predisposed to suffer from stress and another comparatively 
immune? Doctors, researchers, and philosophers have wrestled with this question for 
decades. Answers have been hard to come by, and are anecdotal at best.
Rajita Sinha, PhD ’92, the Foundations Fund Professor of Psychiatry, professor in 
the Yale Child Study Center, and professor of neuroscience, has long been fascinated 
by the fickle nature of mental fortitude. Her studies focus on the characteristics of 
the brain that determine resilience.
Sinha believes she has found the answer. Working with colleagues, she as-
sessed the brains of 30 subjects who presented no prior physical or emotional 
issues. The subjects were exposed to horrific images for a few minutes, then to 
photos unlikely to provoke an emotive response.
Her study revealed how the brain reacts under stress, and what it does to 
adapt and be resilient in response. Findings show brains have a specific resilient 
coping circuit involving a key medial prefrontal region tucked behind the forehead, 
which slowly activates during stress (such as exposure to grotesque visual im-
ages) and helps calm other stress responses. Brains that demonstrated this signal 
during testing exhibited resilient coping behaviors. Those without the signal 
tended to engage in nonresilient behaviors for coping, such as avoidance (defer-
ring or evading an unpleasant task or event that evokes previous trauma).
This finding provided an explanation as to why some people may exhibit greater 
innate resiliency. Those people may be wired to respond effectively to stress, while 
some others aren’t. The benefits extend to training: These brain regions can learn and 
be trained to increase that capacity.
“There are certain basic things we know that work for the brain, if you think 
about resilience. We know that having warm, loving parents is absolutely neces-
sary for a developing brain,” says Sinha. “Studies have shown that trauma and 
neglect, both emotional and physical, are not good for the brain.”
Resilience is one’s ability to recover from a horrible injury, tragedy, or exposure 
to stressors. Those who are resilient are better able to endure hardship. Those with-
out this characteristic are more likely to develop such stress-related illnesses as de-
pression, anxiety, obesity, heart disease, addiction, and even some types of cancers.
Psychological resilience correlates with positivity, and training oneself to 














Breaking the cycle of  
traumatic memories
by courtney mccarroll 
Trials offering ketamine doses to patients suffering from 
post-traumatic stress disorder give some veterans hope 
that they can live a normal life.
After returning home from active duty, soldier Bassheva 
Trenk felt as though something significant had shifted 
inside. Afflicted with intense despair, tortured by lack of 
sleep and vivid nightmares, Trenk was unable to function 
in her everyday life. Even a trip to the grocery store left 
her feeling on edge, hypervigilant, and fearful of anyone 
standing too closely behind her in the checkout line.
“When I got out of the Army, I was in a state of 
complete misery. I had no idea how I was going to get 
through,” says Trenk. Removed from the comfort and 
familiarity of home and reeling from the effects of 
trauma, Trenk struggled considerably. 
Even under ideal conditions, military service takes a 
toll on one’s mental health. War, combat, toxic leader-
ship, and other traumas all challenge the wellness of 
service members and—unfortunately—are not uncom-
mon. Coupled with an individual’s mental makeup prior 
to enlistment, prolonged periods of extreme mental, 
emotional, and physical stress can increase the risk of 
developing post-traumatic stress disorder (PTSD). 
Although PTSD can manifest in a multitude of ways, 
this debilitating anxiety disorder is typically triggered 
by an especially harrowing event—usually one that the 
victim experienced directly or witnessed firsthand. 
Memories or flashbacks of the event can haunt victims, 
leaving them feeling endangered, irritable, and afraid. 
The disorder can be so debilitating that for some, sui-
cide seems like the only recourse. According to the U.S. 
Department of Veterans Affairs, 20 military veterans 
commit suicide on an average day—the majority of 
whom are veterans of the Vietnam War.
In her darkest hour, Bassheva Trenk came danger-
ously close to enlarging that tragic number. Fortunately, 
her attempt was forestalled. After Trenk recovered, a 
close friend begged her to seek help and graciously 
offered to cover Trenk’s living expenses until she could 
get back on her feet. This act of generosity allowed Trenk 
to find her way to Tim Amoroso, a staff affiliate of the 
VA Medical Center (VAMC) in West Haven.
Down the hall from Amoroso’s office, buried deep 
within the sprawling VA Connecticut Healthcare 
complex, flyers and pamphlets adorn the corkboard 
and visitor seating area, offering relief to veterans 
afflicted with treatment-resistant PTSD. Funded in 
part by the multi-institutional Consortium to Alleviate 
PTSD (CAP) and in partnership with the VA and 
Yale University, a team of researchers that includes 
Amoroso investigates a novel approach to treating the 
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“I’ve seen people change before my eyes after an infu-
sion—the tension in their face changes, their affect 
changes, and the next day they are hardly recogniz-
able. It’s exciting and rewarding work to witness this 
and be part of their journey.”
Chadi Abdallah, MD, FW ’13, assistant professor 
of psychiatry, and his colleagues are very optimistic 
about the study thus far and look forward to assess-
ing the comprehensive results in 2020. Ketamine’s 
potential to create positive change in people’s lives is 
enormous. “The success of the [study] may show that 
ketamine could be safely and effectively administered 
to veterans suffering from refractory PTSD,” says 
Abdallah. “It may potentially provide the required evi-
dence to expedite the implementation of this investiga-
tional treatment across the VA health system.”
Although no longer in the study, Trenk still under-
goes infusions once every month or so (in combination 
with her antidepressant medications), she credits keta-
mine with several positive changes. She reports being 
able to sleep more soundly, has noticed a significant 
reduction in the frequency and severity of her anxiety, 
and has even enrolled in a general-studies program at 
her local community college. With renewed confidence, 
Trenk has set her sights on a bright future. 
“Ketamine has had an obvious impact on my life. 
When the effects start to fade away and my anxiety 
and aggression return, that’s how I know how big of 
an impact it has had. I’m not 100 percent recovered, 
but I’m doing so much better now.” /yale medicine 
magazine
Courtney McCarroll is a writer, and works as a program coordinator 
in Yale’s development office.
disorder. It is one of the first clinical trials in the coun-
try to evaluate the effectiveness of ketamine, an anes-
thetic most commonly used in veterinary surgery, as 
part of PTSD therapy. 
The CAP study traces back to a significant 
breakthrough made in the 1990s by John Krystal, 
MD ’84, HS ’88, the Robert L. McNeil, Jr. Professor 
of Translational Research, professor of psychiatry 
and of neuroscience, and chair of the Department 
of Psychiatry. Along with his colleagues at the time, 
Krystal discovered that ketamine has substantial and 
rapid effects on patients suffering from major depres-
sion. Later, Ronald Duman, PhD, FW ’88, the Elizabeth 
Mears and House Jameson Professor of Psychiatry and 
professor of neuroscience; and George Aghajanian, 
MD ’58, HS ’61, FW ’63, professor emeritus of psychia-
try, found that ketamine’s efficacy lies in its remark-
able ability to restore synaptic connections in the brain. 
Dennis Charney, MD, HS ’81, conducted a pilot study 
suggesting that ketamine may also reduce the symp-
toms of PTSD. With these pieces in place, the present 
CAP study was born.
Amoroso—a former Army Ranger (2-75th)—is 
recruiting active-duty personnel and veterans 
between the ages of 18 and 70 who have been diag-
nosed with PTSD but have had little success with 
their prescribed antidepressants. His goal is to enroll 
100 participants. After they are cleared for the study, 
participants are then randomized into three separate 
groups: a placebo group (which receives a saline infu-
sion); a low-dose group (which receives 0.2 mg/kg  
of ketamine); and a high-dose group (which receives 
0.5 mg/kg of ketamine).
When participants like Trenk attend their infusion 
appointments at the VA, they are asked to complete a 
handful of surveys to establish their baseline mood and 
demeanor that day, participate in an interview, and 
discuss any notable side effects or adverse events since 
their last session. Once approved by the VA doctor on 
staff, their infusion begins; it lasts about 40 minutes. 
“Ketamine is safe, well tolerated, and has a rela-
tively minor side-effect profile (compared to the 
traditionally available antidepressants),” explains 
Lynnette Averill, PhD, an associate research scientist 
in psychiatry and member of the VA research team. 
Breaking the cycle of traumatic memories
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Post-traumatic resilience
In U.S. veterans, social connectedness, optimism,  
and a sense of purpose are among the  
characteristics associated with bouncing back from 
trauma—sexual and otherwise.
By Ashley P. Taylor
Many think the biggest threat to military personnel is battlefield death or injury. 
While that is certainly true during wartime, the military spends much of its time 
training. And for U.S. veterans, sexual assault confers a greater risk of post-traumatic 
stress disorder (PTSD) than combat.
Robert Pietrzak, PhD, MPH, associate professor of psychiatry and director of 
the translational psychiatric epidemiology laboratory of the clinical neurosciences 
division of the National Center for PTSD in West Haven, studies veterans, PTSD, and 
resilience. According to his research, sexual assault comes with a 26 percent likeli-
hood of developing PTSD if the trauma occurred during childhood and 36 percent if 
the trauma occurred during adulthood. About 10 percent of veterans have experi-
enced sexual assault, the trauma most strongly associated with PTSD. In compari-
son, combat of any kind—which about 35 percent of veterans have experienced—
comes with an approximately 19 percent risk of developing PTSD. However, this 
figure increases as a function of the intensity of the combat exposure—the most 
heavily exposed veterans have a 35 percent likelihood of developing PTSD.
These data about veterans, PTSD, and resilience come from the National 
Health and Resilience in Veterans Study (NHRVS), which Pietrzak and his col-
leagues have been conducting since 2011. In the NHRVS, nationally representa-
tive samples of thousands of veterans answer survey questions designed to learn 
about veterans’ experiences with trauma, PTSD symptoms, and other factors. 
Researchers then analyze the data to determine which factors are associated with 
PTSD and which with resilience, or the ability to “bounce back” from trauma.
In addition to having experienced such types of trauma as sexual and physical 
assault, other factors that increase the risk of PTSD include being of younger age 
and female.
Nevertheless, many veterans rebound from their ordeals. Among veterans ex-
posed to high levels of trauma of any kind, 70 percent are psychologically resilient; 
in other words, they do not exhibit symptoms of PTSD, depression, or anxiety.
“They basically look as if they hadn’t been exposed to trauma at all,” says  
Pietrzak. His research investigates why it may be possible to use that knowledge 
to help others to bounce back.
Among veterans who participated in the NHRVS in 2011, those who felt they 
had strong social support and a sense of meaning and purpose in life were less 
likely to develop symptoms of PTSD, depression, or anxiety. Optimism and grati-
tude also correlated with greater ability to recover from these symptoms.
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Taking psychiatric  
help to the street
by steve hamm
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Last August, New Haven made the national news in a 
way no city wants when 72 people were poisoned by an 
illicit synthetic cannabinoid called AMB-FUBINACA. 
All over the New Haven Green, people who had ingested 
and/or inhaled the substance fell to the ground, con-
vulsed, and lost consciousness.
Among those who rushed to help them was Emma 
Lo, MD, a fourth-year resident in Yale School of 
Medicine’s psychiatry program and volunteer with a 
street medicine team.
Ambulances, police, and EMTs were scattered all 
over the green when she arrived. She knelt to aid a man 
who had just fallen and was seizing. After a moment, 
she recognized him as a former patient of hers at the 
Connecticut Mental Health Center (CMHC), where she 
had completed a residency rotation. Thinking that 
he was suffering an opioid overdose, she sprayed the 
emergency antidote naloxone up his nose. It didn’t 
work. “I felt very helpless. I wanted to save him, but 
we didn’t know what was going on,” Lo says.
Luckily, nobody died. But stunned city govern-
ment and health care officials developed a strategy for 
avoiding a repeat of that awful day. A number of the 
overdose victims were homeless, so the official response 
included creating one of the few street psychiatry teams 
in Connecticut and hiring Lo to spearhead it. “We’re 
developing a program that can be scaled up if it’s proven 
to be effective,” says Jeanne Steiner, DO, medical direc-
tor of CMHC and associate professor of psychiatry at 
Yale School of Medicine.
Lo has shown a deep concern for people experienc-
ing homelessness ever since she began volunteering to 
help them as an undergraduate at Haverford College. 
“In New Haven, we’re lucky to have a wealth of 
resources for people who live on the street, but there’s 
a gap for people who are chronically mentally ill,” she 
says. “There are clinics that offer mental health care 
but until now there was nobody going out to provide 
care where the people are.”
While national experts estimate that about 25 per-
cent of the homeless population suffers from severe 
mental illnesses, those who care for them say nearly all 
have some sort of mental disorder. “Some are home-
less because of mental illness, and some are mentally 
ill because of the stress and trauma of homelessness,” 
says Philip Costello, an advanced practice registered 
nurse who is the clinical director of homeless health 
care outreach for New Haven’s Cornell Scott-Hill 
Health Center.
Lo had been volunteering on Costello’s team for two 
years as they provided basic medical care for people 
experiencing homelessness—in parks, at soup kitchens, 
at shelters, and on the street. Costello says Lo has a 
low-key style that breaks down the barriers of distrust 
that many homeless people have for police and health 
care professionals alike. “These people are so margin-
alized and they only warm up to somebody who has 
the persona to be sensitive, genuine, and patient—and 
Emma is all of those things,” says Costello.
Lo credits the residency program’s practice of set-
ting aside time for special projects with helping her  
get to where she is today. She crafted her own resi-
dency rotation with the street medicine team. Now, 
thanks to her, street psychiatry is an elective rotation 
for other residents.
Her journey is part of a major new emphasis in the 
psychiatry residency program—where social justice 
and health equity are increasingly baked into the cur-
riculum. Residents interact with patients and commu-
nity leaders throughout New Haven’s neighborhoods. 
To raise their awareness, the residents even try to buy 
healthy meals with the $2.10 per meal that the gov-
ernment provides for food assistance. “We’re expos-
ing the residents to structures in the community that 
affect health so they better understand the issues their 
patients face, can help provide more comprehensive 
patient care, and can advocate for change,” says Robert 
Rohrbaugh, MD ’82, professor of psychiatry and resi-
dency program director.
“Every resident could benefit from this experience,” 
Lo says. “It has taught me so much about understand-
ing people—not just their physical and mental health 
but their whole environment, the social determinants 
of health. Ultimately, you’re learning empathy.”  
/yale medicine magazine
Steve Hamm is a frequent contributor to Yale Medicine Magazine.
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Brain bank aids theories 
on genetics and post- 
traumatic stress disorder
by jenny blair, md ’04
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Yale researchers use a massive brain-tissue repository, 
or “brain bank,” at the VA’s National Center for PTSD to 
postulate generalizations about the genetic origins of 
the condition and its physiological characteristics.
The nightmarish experience of post-traumatic 
stress disorder (PTSD) may be as old as danger itself. 
Survivors of natural disaster, criminal and domestic 
violence, and combat or granted formal psychiatric 
designation only in 1980. PTSD continues to pose a 
formidable challenge to treatment. Guidelines are 
derived more often from expert opinion than from 
trial results and only two medications were FDA-
approved as of late 2018.
Now, drawing on a “brain bank” as well as a  
massive study of veterans, researchers at the School 
of Medicine are mapping PTSD’s genetic and neuro-
biological underpinnings. Their efforts could  
help predict who is susceptible, point the way to 
better treatments, and perhaps teach people how  
to cultivate resilience.  
The aim of these studies is to move from the 
art to the science of psychiatry, says John Krystal, 
MD ’84, HS ’88, the Robert L. McNeil, Jr. Professor of 
Translational Research, professor of psychiatry and of 
neuroscience, chair of the Psychiatry Department, and 
director of the Clinical Neuroscience Division of the VA 
National Center for PTSD. To date, most PTSD research 
has been psychological, not biological, so the field has 
some catching up to do.
“Almost everything that we’re doing is the first of its 
kind,” Krystal says. 
These studies are not merely groundbreaking, 
they’re vast in scale. So far, some 600,000 veterans 
have contributed DNA to the nationwide Million 
Veteran Program (MVP). With this database—one of 
the world’s largest—researchers can detect subtle sig-
nals across thousands of genes. 
Joel Gelernter, MD, the Foundations Fund Professor of 
Psychiatry, professor of genetics and of neuroscience, is 
co-leading a study of this population to uncover genetic 
alterations that show up more often among trauma-
exposed vets with PTSD. These data could one day help 
estimate individuals’ risk of PTSD based on their genes, 
allowing the military to predict that when exposed to 
combat, person ‘A’ has, say, a 20 percent risk of develop-
ing PTSD while person ‘B’ has only a 5 percent risk. 
“Should that affect the role that the person is placed 
in by the military? Is this something we should tell the 
person, so that he or she can make a decision about the 
kind of stresses he’s willing to be exposed to?” Gelernter 
asks. “Those are open questions, but they’re things we’ll 
be facing—if not in the next year, in the next five years.” 
Further, he says, “the genetic information will also aid 
us in understanding the factors that underlie PTSD on 
the one hand and resilience on the other.”
In 1995, then-faculty member Douglas Bremner, MD, 
used MRI to discover the first evidence of changes in 
brain structure in PTSD—a shrunken hippocampus 
in a group of Vietnam War veterans diagnosed with 
the disorder. The hippocampus, one of several brain 
regions involved in PTSD, helps researchers interpret 
loci in the brain as vulnerable trauma or not.
Thanks to a brain-tissue repository, or “brain bank” 
of PTSD patients, researchers can now explore the dif-
ferences between brains from people with PTSD and 
those without. The National PTSD Brain Bank is housed 
within the National Center for PTSD (NCPTSD) and 
the Boston VA Medical Center. The clinical neurosci-
ence division of NCPTSD is based at the VA Connecticut 
Healthcare System and the Yale School of Medicine; 
Brain bank aids theories on genetics and post-traumatic stress disorder
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  John Krystal
 “PTSD has a lot to  
do with the capacity  
  to bounce back. 
it serves as the primary research laboratory for the 
National PTSD Brain Bank. 
Instead of studying genetic alterations like Gelernter 
and his colleagues, Ronald Duman, PhD, the Elizabeth 
Mears and House Jameson Professor of Psychiatry and 
professor of neuroscience, is examining the activity 
of thousands of genes by measuring the mRNA tran-
scripts and proteins those genes express in hotspot 
brain regions. 
By comparing differences in gene expression in the 
brains of patients who were diagnosed during their lives 
from PTSD, those who had major depression, and those 
who did not receive a psychiatric diagnosis, research-
ers hope to illuminate where PTSD overlaps with other 
would actually target these networks and hub genes,” 
Duman says.
Given how few PTSD medications we currently 
have, new ones would be no small advance. But as 
we map the disorder’s genetic and protein correlates, 
we’re likely to learn more about the origins of resil-
ience, too. In its way, resilience is as big a mystery 
as the frightening symptoms of PTSD. Why do some 
people manage to weather terrible traumas and return 
to a healthy baseline? 
“Some of the factors that are going to be implicated 
in the risk and the vulnerability to PTSD aren’t just 
going to be things that help people be less anxious. 
They’re also going to be things that help people to 
psychiatric disorders. They also hope to delineate sub-
types that might respond differently to treatments.
With the RNA from tissue samples in each of five 
regions of 200 brains under study, Duman estimates that 
the project is amassing 50 million data points about the 
expression levels of 15,000 genes for each brain region 
of each subject. To analyze this massive amount of data, 
he is collaborating with the bioinformatics group in the 
laboratory of Hongyu Zhao, PhD, chair and Ira V. Hiscock 
Professor of Biostatistics, professor of genetics, and of 
statistics and data science. The project will gradually 
untangle networks of genes whose expression is altered 
in concert with PTSD, as well as identifying so-called 
hub genes that play an outsized role. 
“If we understood the gene networks and biochemi-
cal changes that are critical for PTSD pathophysiology, 
then we could start to think about treatments that 
cope and adapt and recover quickly,” Krystal says. 
“What we find in relation to the genetics of PTSD is 
likely to have implications not only to PTSD, but … 
[for] how people face life challenges and grow from 
these experiences.” 
That too should inform PTSD treatment. When suc-
cessful, Krystal says, treatment pulls the patient away 
from rigid thinking—what some people call the “black 
hole” of trauma or depression—giving him or her the 
“capacity to approach the world in a much more adap-
tive and flexible way … learning to see the world as 
both dangerous and safe.” 
“PTSD,” he adds, “has a lot to do with the capacity to 
bounce back.” /yale medicine magazine
Jenny Blair is a frequent contributor to Yale Medicine Magazine.
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by katherine l. kraines
Computational  
psychiatry: Modeling the 
brain’s neural circuitry  
Alan Anticevic and John Murray have combined 
efforts in order to understand the biology that 
underpins the brain’s neural system.
Imagine a mathematical approach to brain research 
that models the mechanistic basis of brain disorders. 
Then envision a future in which these models are used 
to offer personalized medicine to individuals with 
mental health issues. The field of computational psy-
chiatry, a recent subdiscipline that develops and uses 
mathematical models of brain function and structure 
to explain dysfunction in psychiatric disorders, shows 
great promise in meeting those needs. 
Within the Department of Psychiatry’s Division 
of Neurocognition, Neurocomputation, and Neuro-
genetics, or N3 Division, two researchers are spear-
heading research in collaborative computational 
psychiatry with the goal of making inferences about 
the underlying biology of the brain’s neural system. 
Alan Anticevic, PhD, assistant professor of psychia-
try and of psychology, and co-director of N3, leads a 
clinical neuroimaging laboratory focused on severe 
psychiatric illness; and John Murray, PhD ’13, assistant 
professor of psychiatry, of neuroscience, and of phys-
ics; directs a laboratory that employs computational 
modeling to improve understanding of neural function 
and dysfunction in psychiatric disorders. 
Before joining forces, both scientists had observed 
that many neuroimaging findings, while powerful 
in mapping the brain, lack a mechanistic interpreta-
tion. Moreover, both saw a critical need to translate 
theoretical findings to clinical research in a prin-
cipled way. “When we first met, it was obvious to us 
that a computational-empirical partnership was one 
of the few ways we could make a practical impact,” 
Anticevic says. 
While neuroimaging has come a long way in the last 
century, spatial and temporal resolutions are still lim-
ited; no human imaging can “see” at the level of indi-
vidual neurons. “Even when we can experimentally 
manipulate brain function with pharmacology, it’s 
difficult to make inferences about what’s happening 
at the level of neurons,” says Anticevic. “Even a single 
unit of fMRI measurement, a voxel, has a rich circuit 
landscape made of millions of neurons and kilometers 
of axons that we just can’t see.”
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To bridge the gap between the seen and unseen, 
Murray’s team creates mathematical models of the 
brain’s electrochemical activity at the cellular level. 
“The models are used to study how perturbations at 
the mechanistic level can propagate upward to impact 
brain-wide functioning,” Murray says. “Studying 
the properties of neurons and synapses allows us 
to describe those interactions and activity through 
dynamic equations that resemble equations for resis-
tors and capacitors.” Murray’s team then builds models 
that incorporate some of the details that simulate neu-
ral activity, which are later evaluated with neuroimag-
ing experiments.
“There are many ideas about what may happen at 
the neuronal level that drives the cascade of altera-
tions that produce abnormal behavior,” says Anticevic. 
“For instance, one prominent hypothesis in psychosis 
research is that there may be something ‘off’ in the 
way the NMDA receptor is working.” 
The NMDA receptor, or NMDAR, is a protein molecule 
that lies within almost all brain-cell membranes and 
mediates synaptic interactions. Anticevic describes it as 
a tiny logical gate with two requirements for excitation: 
first, specific molecules must bind to it; second, it must 
receive a signal from another cell. When these events 
co-occur, the channel opens to allow the flow of posi-
tively charged ions, thus changing the cell’s polarization. 
“With psychosis, we hypothesize that something goes 
quite wrong with this core computational machinery,” 
he says. Along with others in the field who are test-
ing this hypothesis, John Krystal, MD ’84, HS ’88, the 
Robert L. McNeil, Jr. Professor of Translational Research, 
professor of psychiatry and of neuroscience; and chair 
of the Department of Psychiatry, observes that giving 
healthy individuals low doses of ketamine temporarily 
blocks a specific kind of NMDA receptor found in cells 
that calm the brain. The result is a transient state with 
some of the behavioral symptoms associated with psy-
chosis or schizophrenia.
Anticevic’s research includes administering keta-
mine in order to study the immediate effects of the 
drug that induce psychosis. “We observe pharma-
cological effects with imaging and behaviorally,” he 
says. As the behavioral effects of ketamine occur, spe-
cific changes in neural activity across the brain are 
captured by fMRI. “With evidence from experiments, 
we can put a hypothesis into a mathematical frame-
work that predicts what would happen if we block 
NMDA receptors everywhere equally or somewhere 
more preferentially,” says Anticevic. 
“Only recently has modeling been able to make 
experimentally testable predictions for neuroimag-
ing,” Murray says. “Being able to design experiments 
and analyses around models is critical because we need 
these particular types of data and analyses to itera-
tively test and refine the models and improve them.”
Computational psychiatry hasn’t yet crossed the 
bridge into clinical practice. However, the researchers 
hope that their work will reveal the diverse mecha-
nisms of brain disorders and provide models that 
can be used to make predictions at the level of the 
individual patient. These models in turn will mini-
mize clinical guesswork regarding causes and treat-
ments. The National Institute of Mental Health (NIMH) 
actively supports research in the field of computa-
tional neuroscience.
Anticevic noted that collaborative research within 
the N3 framework offers a multidisciplinary approach 
that attracts researchers from physics, mathematics, 
computer science, computer engineering, neurosci-
ence, psychiatry, clinical psychology, and cognitive 
neuroscience. “The problem doesn’t care about your 
background,” says Anticevic. “There isn’t any one skill 
set that can tackle this challenge. It’s bigger than any 
one lab.” /yale medicine magazine
Katherine L. Kraines is a frequent contributor to Yale Medicine 
Magazine.
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Why concussions  




The National Football League’s 2017–2018 season 
brought a stunning first-ever Super Bowl win for the 
Philadelphia Eagles—and an equally stunning number 
of head injuries. The 281 reported concussions repre-
sent a 13.5 percent increase in such injuries over the 
previous season and an overall five-year high. While 
the League’s 47 rule changes since 2002 have done little 
to reduce concussion rates, the steady upswing keeps 
the issue on the public health radar.
Sports-related concussions are not limited to profes-
sionals, nor are their residual effects. The Centers for 
Disease Control and Prevention estimates that some 
135,000 children between the ages of 5 and 18 are 
treated in emergency rooms for sports-related con-
cussions every year. The National Collegiate Athletic 
Association sees more than 10,000 of these injuries 
each year. In all of these groups—youth, collegiate, and 
professional athletes—a link between concussion and 
depression is apparent. What’s more difficult to tease 
out is the precise relationship between the two.
“Most athletes after a concussion actually recover 
quite quickly and don’t have these residual symp-
toms,” says Franklin Brown, PhD, assistant profes-
sor of neurology and chief of the Division of Yale 
Medicine Neuropsychology. “There’s been multiple 
areas of research determining why others don’t 
recover so quickly.”
One such study, published in the journal Clinical 
Neuropsychologist in March 2013, drew on previous 
research to conclude that 15 to 30 percent of people 
who suffer a mild traumatic brain injury report linger-
ing symptoms.
An estimated 18 percent of adults develop new-onset 
depression after a concussion. But definitively “new” 
cases of depression can be tough to identify after con-
cussion. Depression can often appear to be the result of a 
head injury when in fact it was only exacerbated by the 
injury. “The vast majority of people who don’t recover 
quickly usually have preexisting mental health issues,” 
says Brown. Research shows that pre-existing depres-
sive and pre-existing concussive symptoms are both 
major predictors of post-concussion depression.
Concussive symptoms don’t always mean a history 
of concussion. Many people in the general population 
experience such common concussion-like symptoms 
as headache, fatigue, and dizziness from time to time. 
The same is true of depression. Often, people live with 
these symptoms and never report them. A concus-
sion can draw patients’ and doctors’ attention to these 
symptoms for the first time, though they may have 
been present before.
A small study illustrated the prevalence of “post-
concussion-like” symptoms and their overlap with 
depression in a population with no history of concussion. 
The healthy study participants completed standard post-
concussive and depressive symptom inventories. At least 
one of the concussive symptoms had been expressed by 
36 percent of the respondents in the last two weeks. Up 
to 15 percent had experienced the more severe symptoms. 
What’s more, the researchers found significant overlap 
between those who reported concussion-like symp-
toms and those who reported depressive symptoms. The 
research didn’t establish a causal relationship, but rather 
underscored the correlation more vigorously.
While researchers don’t entirely understand this 
interplay, they have recognized it for some time. 
“Neurological and psychiatric symptoms and diagnoses 
very commonly run together,” says Deena Kuruvilla, 
MD, assistant professor of neurology. “For example, 
depression and anxiety are some of the biggest risk fac-
tors for developing chronic migraine.”
She adds, emphasizing their physiological link, 
“Antidepressants can be helpful for treating migraine, 
depression, and anxiety.” 
A recent review in Neural Regeneration Research 
explores a possible mechanism for the overlap, inflam-
mation. The study found a pro-inflammatory state 
present in the brain in both depression and traumatic 
brain injury. Each condition can exacerbate the other. 
“The pro-inflammatory state can persist for months to 
years after injury,” says Kuruvilla.
Regardless of whether the neurological or the psy-
chiatric symptoms come first, these issues can escalate 
and multiply if unchecked. “Depression, mood change, 
headache—these are the things we can treat after 
concussion,” says Kuruvilla. “If these symptoms go 
untreated, the patient’s quality of life can deteriorate.”  
/yale medicine magazine
Sonya Collins is a frequent contributor to Yale Medicine Magazine.
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by christopher hoffman
When researchers  
listen to people who 
hear voices 
The line between mental illness and genius has long 
been known to be razor-thin. Yale researchers stum-
bled upon evidence of this fragile boundary while 
researching auditory hallucinations in schizophrenia.
The last thing you’d expect Yale School of Medicine 
brain researchers to do is hang around with psychics, 
let alone enlist them in their research. But that’s exactly 
what Albert Powers, MD, PhD, HS ’16, assistant profes-
sor of psychiatry, and Philip Corlett, PhD, FW ’10, asso-
ciate professor of psychiatry, have been doing since 2014.
Even more surprising, the unusual partnership has 
produced insights that could one day revolutionize the 
diagnosis and treatment of schizophrenia.
“The irony is not lost on me,” says Corlett, with a 
broad grin.
Corlett and Powers’ unlikely journey into the 
world of psychics began when they resolved to bet-
ter understand the phenomenon of schizophrenic 
patients who experience auditory hallucinations, col-
loquially known as “hearing voices.” The researchers 
wanted to study people who’d had similar experiences 
but didn’t seek or appear to need treatment. Thanks 
to recent research, the pair knew that such people are 
surprisingly common. As much as 8 percent of the 
population reports experiencing auditory hallucina-
tions on a regular basis (13 percent hear them at least 
occasionally), compared to just 1 percent who are 
diagnosed with schizophrenia. Where to find them? 
The pair considered charismatic Christians, practitio-
ners of Santeria, practitioners of voodoo, crystal heal-
ers, and self-proclaimed druids. None panned out.
One day while riding the bus home, Corlett noticed 
the large number of storefronts offering psychic read-
ings. Perhaps people who go to psychics would fit the 
bill, he thought. Powers and Corlett reached out to 
the president of the American Association of Psychics’ 
Connecticut chapter, who informed them they were 
looking for clairaudients—psychics who use voices 
in their heads to give readings and, the clairaudients 
believe, communicate with the dead. 
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Powers started going to association meetings and 
psychic fairs with another researcher, Adina Bianchi, to 
talk with clairaudients, Corlett says. Almost immedi-
ately, they believed that they had found their study sub-
jects. To confirm their hunch, the researchers asked the 
psychics to undergo a battery of tests, including brain 
scans and an extensive survey that included questions 
designed to unmask fakers. The psychics passed with 
flying colors, leading Corlett and Powers to conclude 
that they hear voices much like schizophrenic patients 
do, but with key differences—the voices are friendly, 
they can be controlled, and hearers consider them a gift 
instead of a burden.
The clairaudients have proven enthusiastic par-
ticipants, Corlett adds. “One of the wonderful things 
about working with this group is they are delighted 
that we are taking them seriously,” he says. “We said, 
‘We have no interest in debunking. We agree to dis-
agree [on the cause of the voices], but we believe you 
are having real experiences.’”
One volunteer for the study was Brittany Quagan, 
who says she first heard voices as a young girl. At 15 
or 16, the voices became a serious problem, leading 
to years of therapy and drug treatment. Her break-
through came at 21, when a work colleague who was a 
psychic suggested the voices were evidence of psychic 
powers, not mental illness. Quagan says she became 
convinced that her friend was right after Quagan 
recounted facts about a co-worker’s recently deceased 
relative to the surprised co-worker. 
After her revelation, Quagan says that she quickly 
gained control of the voices—one is a man, the other a 
woman with a British accent. She stopped taking med-
ication and turned her life around. She quit her job and 
began giving psychic readings full time.
“I call them guides,” she says of her voices. “It’s 
almost like calling a friend, ‘Hey, come here!’ That’s 
how I connect to them.”
Powers and Corlett’s study subjected the psychics, 
people diagnosed with schizophrenia, and non-voice-
hearers to a simple Pavlovian test devised at Yale in the 
late 19th century. A light and a sound are paired, with 
the sound becoming steadily fainter and eventually 
ceasing. The brain, however, continues to perceive the 
sound even when it’s not there. Researchers can use 
the test to induce a minor hallucination—hearing a 
sound when there is none—in anyone.
The test results were startling, the patients with 
psychosis and the psychics were five times more likely 
than non-voice-hearers to perceive a sound when 
there was none. Brain scans done during the testing 
showed that the same parts of the two groups’ brains 
were activated when they perceived sounds that were 
not there.
The findings, which Corlett and Powers published 
in the August 11, 2017, issue of Science magazine, have 
huge potential for the diagnosis and treatment of 
schizophrenia. Treatments could eventually include 
devices to short-circuit brain activity that causes hal-
lucinations and behavioral strategies to forestall psy-
chosis, the researchers say. 
“I’d say we’ve made a massive leap forward in terms 
of conceptual understanding, and what we’re trying to 
do next is turn that into something useful for patients,” 
Corlett says.
The psychics will remain vital partners in their 
ongoing work, both men say. Powers has gone a step 
further, he has hired voice hearer and test subject 
Quagan, who is in the final stages of obtaining her 
therapist’s license, as his new lab manager. While 
Quagan remains convinced that her voices and psychic 
powers are real, she has come to accept that they may 
have a neurological component. 
“Whether what we [psychics] do is real or not, I’m 
not going to argue,” Quagan says. “We all have differ-
ent beliefs. But the underlying narrative for all of us is 
that we found a way to cope. We found a way to work 
with our experiences. Because of that, we were able to 
move away from what could have been a downward 
spiral.” /yale medicine magazine




Speeding treatment  
blunts the worst of 
schizophrenia
by john curtis
A few years ago, a young man and his family came to 
the Connecticut Mental Health Center (CMHC) to seek 
help. The college student was having troubles that 
seemed to go beyond the run-of-the-mill concerns of a 
young adult.
“It was clear to us that the reason he could not keep 
up in school was not depression or anxiety, but an 
emerging psychotic disorder,” says Vinod Srihari, MD, 
HS ’03, FW ’05, associate professor of psychiatry.
The young man was hearing voices, a classic sign of 
schizophrenia. The voices commented on whatever he 
was doing in the moment, disparaged his appearance, 
and ordered him to do things he didn’t want to do.
Srihari’s first step was to make the patient 
feel comfortable with treatment, which included 
psychotherapy and antipsychotic medication to quell 
the voices. He also helped the young man’s family 
understand what was happening.
Between four and five months passed from the onset 
of symptoms to treatment. This may seem like a long 
time, but Srihari says average delays in typical care set-
tings can be much longer. Though this pathway to treat-
ment was relatively short, Srihari believes this period, 
called the duration of untreated psychosis (DUP), is still 
too long. This is an ongoing area of research, but studies 
have linked early treatment to better outcomes. 
For the past four years, Srihari has led MindMap, a 
study funded by the National Institutes of Health, to 
test that theory. Previously, he launched an interdisci-
plinary program called Specialized Treatment Early in 
An interdisciplinary program called Specialized 
Treatment Early in Psychosis, founded by Vinod Srihari, 
MD, is helping speed treatment of schizophrenia.  
How quickly the condition is diagnosed and treated 
can determine a patient’s odds of living a relatively 
normal, albeit medicated, life.
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Psychosis (STEP), which demonstrated that a specialty 
team-based model of care resulted in better outcomes.
Srihari launched STEP in 2006, after securing 
approval from the state of Connecticut to provide care to 
all youth with new-onset psychosis at CMHC, regardless 
of insurance coverage. The center was already open to 
those on Medicaid or without insurance, and STEP was 
permitted to care for those with various commercial 
insurance plans. STEP reflects a collaboration between 
the Connecticut Department of Mental Health and 
Addiction Services and the Department of Psychiatry. 
“We start a treatment plan that is focused on helping 
them comply with medication and stabilizing their 
symptoms, and we start work on getting them back to 
work or school,” Srihari says.
Each person has at least a one-in-100 chance of 
developing schizophrenia in their lifetime. Without 
early and effective treatment, the symptoms can  
render them unable to work, study, or maintain 
friendships. “This is a disorder that punches well 
above its weight in terms of burden, even though  
it is not as common as other mental illnesses,”  
Srihari says. Its cause remains a mystery, although 
researchers have identified genetic and environ- 
mental risk factors.
First termed schizophrenia by early 20th-century 
Swiss psychiatrist Eugen Bleuler, it is now considered 
a group of disorders that share signs (observable by 
others) and symptoms (subjective experiences) that 
include hallucinations, delusions, and the inability to 
Speeding treatment blunts the worst of schizophrenia
  Vinod Srihari
 “Schizophrenia spectrum disorders  
denote a very diverse group of  
   what are probably many different  
  diseases with distinct causes;  
nevertheless, this is still a meaningful  
   construct that can tell us a lot about  
 the kinds of experiences people are  
   undergoing, the challenges they  
  are likely to have, and the treatments  
    that will be helpful. 
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take pleasure in everyday life, trouble focusing, and 
loss of working memory.
“Schizophrenia spectrum disorders denote a very 
diverse group of what are probably many different dis-
eases with distinct causes,” Srihari says. “Nevertheless, 
this is still a meaningful construct that can tell us a lot 
about the kinds of experiences people are undergoing, 
the challenges they are likely to have, and the treat-
ments that will be helpful.”
Because schizophrenia strikes when people are 
young, usually in adolescence or early adulthood, it 
can be hard to distinguish the symptoms from garden-
variety teenage angst.
“They may withdraw socially from their friends. 
They might struggle in school,” Srihari says. “It can 
look like depression or anxiety, which they may be 
experiencing, but psychotic symptoms can be less evi-
dent, especially when individuals may feel less com-
fortable talking about unusual subjective changes.”
Getting patients to treatment can be a challenge. 
Some may not want to admit that they have a mental 
illness, or fear that they’ll be locked up. That period 
between diagnosis and treatment—the DUP—is crucial, 
Srihari says, because that’s when patients are at the 
highest risk of aggression, suicide, losing jobs, losing 
relationships, and dropping out of college.
“There is a subjective journey within which the young 
person and the family come to figure out this is an illness 
and professional assistance is necessary,” Srihari says. 
“It can begin in a jarring manner, with a police officer 
finding you on the street and taking you to the emer-
gency room or to jail. However, if you’re in a state like 
Connecticut, you may have a jail diversion officer who 
says you don’t belong in jail, you need treatment.”
To shorten the pathway to treatment, Srihari and 
colleagues launched the MindMap study in 2015. 
MindMap, which covers New Haven and nine neigh-
boring towns, is based on Norwegian research findings 
that showed earlier access to treatment resulted in bet-
ter outcomes. MindMap has three prongs: first, a social 
media campaign raises awareness of psychosis among 
young people, their friends and family, clinicians, and 
others; second, the program reaches out to commu-
nity stakeholders who are in contact with adolescents 
and young adults—such as mental health providers, 
primary care providers, clergy, college counselors, 
police, and community groups; third, MindMap tracks 
how many phone calls come into the program and how 
many calls transpire between first contact and care. 
There’s no difference in the care provided—the variable 
is getting patients into treatment quickly.
A control program, which offers treatment but 
no campaign to reduce waiting time, is underway in 
Boston. The New Haven program ended in February 
2019, but interim results are promising, Srihari says. 
Two and a half years in, the median delay from onset 
to prescription of an antipsychotic dropped from about 
150 days to 40 days.
“It remains to be seen—if we get our act together and 
provide early intervention across the U.S.—whether it 
will change the face of chronic schizophrenia,” Srihari 
says. “The real gains will be realized over a 20-, 30-, 
40-year lifespan, when our hope is that people are less 
likely to be on disability and will retain their employ-
ment, retain their insurance, and retain their families.”
As a success story, Srihari points to the young man 
who came to STEP a few years ago. After two years, he 
“graduated” out of STEP and now receives treatment 
from a community physician. He will need treatment, 
including antipsychotic medication and psychotherapy, 
for the rest of his life. Yet his symptoms have receded, 
and he has a job that involves helping others get reha-
bilitative services.
“For us, this is an arc that has been fulfilling,” 
Srihari says. “He has a job, he has commercial health 
insurance—he is a contributing member of society and 
does not need intensive or specialized treatment with 
us anymore.” /yale medicine magazine
John Curtis is a frequent contributor to Yale Medicine Magazine.
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Tackling addiction with 
treatment and predictive  
outcomes modeling 
Researchers provide insights into the biological pro-
files the underlying risk of substance use relapse, 
while treatment methods offer patients new options. 
From the predictive to the prescriptive, advances in the 
science of addiction treatment are bringing us closer 
to delivering on the long-implicit promise that func-
tional recovery from substance use disorders is pos-
sible. Mapping neural profiles to identify individuals 
at risk of addiction to certain drugs, investigating the 
underlying causes of relapse, and expanding the reach 
of successful behavior modification techniques all give 
patients with substance use disorders cause for hope.
your own neurological map 
Researchers in the lab of Kathleen Carroll, PhD, the 
Albert E. Kent Professor of Psychiatry, combined 
machine learning and neuroimaging to build a brain-
behavior model that predicted cocaine abstinence 
among a group of 53 people who were entering treat-
ment for cocaine use. The researchers applied this 
model to neuroimaging data from a group of 45 indi-
viduals who were also entering treatment, and found 
their prediction of who would abstain from cocaine 
during treatment to be 70 percent accurate. Led by 
Sarah Yip, PhD, FW ’15, assistant professor of psychia-
try, and in the Yale Child Study Center; in collabora-
tion with Dustin Scheinost, PhD ’13, FW ’15, assistant 
professor of radiology and biomedical imaging, and in 
the Yale Child Study Center, the team laid the ground-
work for evaluating mechanisms that could guide the 
treatment of patients.
“We don’t have a good predictor of who will benefit 
from a course of treatment,” says Yip, “Using these 
data analysis approaches, we hope to one day be able to 
tailor treatment to individuals.”
Yip’s research points in the direction of a person-
alized neural map that may one day save patients 
valuable time, money, and resources—not to mention 
heartbreak. Published online in the American Journal 
of Psychiatry on January 4, 2019, the prediction of 
cocaine abstinence based on the connectome—a com-
plete map of neural connections in the brain—also  
provides insight into the neurobiology of recovery, 
which may speed the development of novel interven-
tions to further improve outcomes. 
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While researchers like Yip develop predictive tools to aid in 
addiction treatment, other clinicians and researchers are 
focusing on another problem area—the threat of relapse 
once a patient successfully completes a course of treatment. 
“Our targets are channels that influence dopamine activity 
in the brain,” says Nii Addy, PhD ’07, associate profes-
sor of psychiatry and of cellular and molecular physiol-
ogy. “Certain cues can trigger drug relapse—think about 
the smoker who’s attempting to quit, and then returns 
to a bar to socialize with friends, only to find themselves 
smoking again. We’re using rodent models to understand 
what happens in the brain that allows cues to bring about 
that relapse. A great deal of research has shown that brain 
dopamine levels increase in the presence of drug cues.  
So channels that decrease brain dopamine concentrations 
could be potential therapeutic targets for drug relapse.”
Addy’s project, funded in part by a grant from the 
National Institutes of Health, focuses on L-type calcium 
channels in cells, which are channels that allow calcium 
to enter the cells. These channels affect how dopamine 
(the neurotransmitter most responsible for stimulating 
the reward system within the brain) acts neurologically.  
At present, scientists mostly understand the roles dopa-
mine plays in motivating reward, regulating mood, and 
fostering learning. Figuring out when and how to regu-
late dopamine could allow scientists to develop treat-
ments that short-circuit addictive behavior as well as 
lower the risk of relapse.
Addy’s interest in the neurological makeup of 
substance use disorder was sparked when he was an 
undergraduate at Duke University. He worked in a lab 
where researchers studied how nicotine could reverse 
the cognitive deficits associated with schizophrenia 
and antipsychotic medications.
One discovery that surprised Addy during his most 
recent research is that blocking the calcium channel 
decreased the frequency of relapse among subjects but 
increased dopamine levels. “That was the opposite of 
what we expected, given current understanding of 
how dopamine operates,” Addy says.
reprogramming neural pathways
Carroll has spent nearly 30 years developing a pro-
gram called Computer Based Training for Cognitive 
Behavioral Therapy, or CBT4CBT. The program takes 
a model proven to facilitate positive changes in a per-
son’s actions—cognitive behavioral therapy—and offers 
it online to patients with a substance use disorder. 
Developed and tested with support from the National 
Institute on Drug Abuse and the National Institute on 
Alcohol Abuse and Alcoholism, CBT4CBT makes a stan-
dardized, effective form of treatment available to people 
wherever and whenever they need it; it is particularly 
promising in reaching underserved populations. 
CBT4CBT started when Carroll saw the potential for 
technology-assisted treatment in the early 2000s.  
“My daughter loved learning to read while sitting on my 
lap using the Clifford the Big Red Dog program on the 
Public Broadcasting Service website,” says Carroll.  
“I realized that CBT could be taught and practiced 
remotely using those new multimedia tools. We think 
that by demonstrating cognitive and behavioral self-
control skills and strategies in an engaging, fun way—for 
example, by including a series of videos that show people 
using the skills in real-world challenging situations—
we’ve developed a very powerful tool. Here we are nearly 
20 years later, and the technological opportunities for 
treatment have far exceeded early expectations.”
Asked how CBT4CBT compares to other forms of 
treatment for substance abuse disorders, Carroll is 
optimistic. “We spend billions in the U.S. on treat-
ments that haven’t been proven or even shown not to 
work, like detoxifying people without follow-up,” she 
says. “We have tested CBT4CBT extensively in over 
seven randomized clinical trials, and have shown that 
it can have better outcomes than standard outpatient 
treatment while costing a lot less. Plus, patients really 
like it, which is the bottom line.”
There is still much to learn about how bodies respond 
to treatment for substance use disorders. Yip, Carroll, 
and Addy are all bringing medical science and the clini-
cal application of that science closer to the day when 
substance use disorder is seen as a treatable chronic dis-
order that can be managed, enabling people to resume 
happy, productive lives. /yale medicine magazine
Adrian Bonenberger is the editor of Yale Medicine Magazine.
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He never thought of him-
self as a collector. He just 
bought pieces he enjoyed 
and could share with oth-
ers who might appreciate 
medical history, art, or 
representations of illness. 
Humorous, serious,  
valuable, or sad: if a draw-
ing or print caught his 
eye, Clements Collard Fry 
(1892–1955), MD, head 
of the Division of Mental 
  Clements Collard Fry slowly amassed an astonishing  
collection of prints and drawings that he  
   bequeathed to the university after his death
  By Adrian Bonenberger
  The Clements  
Collard Fry Collection
Hygiene in the Department 
of University Health at Yale 
after 1937, made an effort 
to acquire it. 
By the end of Fry’s life, 
he’d accumulated over 
2,000 prints, covering five 
centuries and the work of 
hundreds of artists. Susan 
Wheeler, the Medical 
Historical Library’s cura-
tor of prints and drawings 
and historical medical 
posters, knows more 
about Fry’s collection 
than anyone else alive, 
having spent a great deal 
of time with it. She wrote 
a book on the subject—
Five Hundred Years of 
Medicine in Art—which 
was published in 2001.
“Clements Collard Fry 
developed an interest in 
collecting fairly early in 
his life, first focusing on 
manuscripts and editions 
of Silas Weir Mitchell, a 
pioneer in the treatment 
of nervous disorders and a 
prominent literary figure,” 
said Wheeler. “But as 
Mitchell’s works became 
harder to find and more 
expensive, Fry turned to 
rare medical prints. Over 
time that interest devel-
oped in sophistication, 
and what you see in the 
collection today is the cul-
mination of a lifetime of 
collecting medical art.” 
World War II seemed 
to be a turning point for 
Fry as a collector. While 
working in Washington, 
D.C., with the National 
Research Council, Fry 
became immersed in the 
“The Crack-Up,” by Corpo-
ral Wayne Seese, uses an 
unusual palette to depict  
a public moment of  
private anguish amid the 




collection of prints and 
drawings at the National 
Gallery of Art. An unusual 
drawing from this time, 
“The Crack-Up,” portrays 
a U.S. soldier who has a 
breakdown during the 
Pacific campaign. Taken 
from an event that the 
artist (Corporal Wayne 
Seese, U.S. Army) wit-
nessed, “The Crack-Up” 
was shown as part of a 
late 1945 exhibition U.S. 
Marine Combat Art, that 
included 130 drawings 
by 22 Marines. When Fry 
contacted the artist to 
learn the story behind the 
drawings, Seese replied:
The “Crack-Up” came 
from a scene I witnessed on 
the island of New Britain, 
after the Cape Gloucester 
campaign … One night as 
we sat in our … tent, bed-
lam broke out across the 
street at sick bay. Rushing 
over there, we came upon 
the scene I have put down  
on paper.
Yelling, sobbing, and 
talking, the kid was held 
down by a couple of his 
buddies while the doctor 
prepared a sedative. The 
scene was pretty weird 
with hundreds of fel-
lows drawn by morbid 
curiosity standing in  
the darkness …
The kid was a rugged- 
looking boy about 
nineteen or twenty, a 
messman [entry-level 
ABOVE One of the prints  
Fry collected on the subject 
of madness.
LEFT The collection has 
pieces of historical signifi-
cance, such as those dealing 
with 18th- or 19th-century 
American history.
assistant to the ship’s 
steward of a merchant 
marine vessel] at the time. 
He stepped out of his tent 
and in the darkness  
ran into a tree and went 
to pieces. Rumor was that 
he had just received a 
letter that both his sister 
and father were killed  
in an accident, but I  
don’t know.
“Perhaps to a surpris-
ing extent, World War II 
was viewed through 
drawings made by com-
bat artists,” said Wheeler. 
She explained that iconic 
photographs captured the 
public’s attention, but that 
handmade illustrations 
of events still provided 
civilians back home with 
powerful visualizations of 
the war. 
The school continues to 
acquire prints and draw-
ings through gifts and 
endowments, adding to 
the collection’s diversity. 
They reflect Fry’s aesthetic 
and professional interests. 
“The items we have 
acquired over the past 
50 years build on what 
Dr. Fry’s collection was,” 
said Wheeler, “and help 
bring it into the present. 
Dr. Fry used to show these 
prints to his colleagues and 
students—he liked people’s 
seeing them and delight-
ing in their stories. We do 
what we can to continue 
that legacy.”
LEFT Clements Collard 
Fry’s collection included 
many period pieces de-
scribing scenes or profiles 
(often satirical in nature) 
that illuminated a disease 
or disorder. Relatively 
few, however, described 
maladies contemporary 































 A well-balanced life: 
Sharon Weinstein’s  
 long career of service 
»
sharon weinstein, md ’78, knew that she wanted to 
be a psychiatrist at the age of 10. She read Nancy Drew 
and The Hardy Boys, but also Scientific American and 
Freud’s books on dreams. She idolized pioneering  
scientists like Marie Curie, wrote to Jonas Salk, and 
was thrilled when the discoverer of the first polio vac-
cine replied. “From early childhood, I have always been 
interested in how people live their lives,” Weinstein  
said, “learning how they face challenges and overcome 
adversity to realize their dreams.”
Service and education were 
woven into the family’s culture. 
“In Europe, my grandmothers 
were denied educational oppor-
tunities,” Weinstein said. “We 
understood what a privilege 
education was.” Her parents 
ensured their children engaged 
with a spectrum of subjects, in 
school as well as at home and 
in the community. Weinstein 
thrived with the multidiscipli-
nary concept—it would in fact 
become a pillar of her profes-
sional focus. “I was fascinated 
by connections between mind, 
brain, body, and society,” she 
said. “I think that was fostered 
by a range of life events in a 
large, multigenerational family.”
In many ways, Weinstein is a 
product of her environment. Her 
psychiatry practice exists at the 
intersection of science and art 
and of the personal and environ-
mental, where culture, spiritual-
ity, and medicine meet. These 
elements were embedded in her 
heritage and ignited by her com-
ing of age against the backdrop 
of a shifting world. In the 1960s, 
Weinstein attended a “large pub-
lic high school marked by cul-
tural, ethnic, and socioeconomic 
diversity,” and she began college 
in an era of political upheaval 
and social change, particularly 
for women. Some regarded 
Harvard’s introduction of coedu-
cational housing her sophomore 
year there as an unwelcome 
break with tradition. Women 
were gaining admission to medi-
cal schools in greater numbers, 
but at Yale, Weinstein remembers 
Curiosity served her well. The 
Massachusetts Psychiatric Society 
recently honored her with the 
2018 Award for Outstanding 
Psychiatrist in Education for her 
multifaceted teaching and pro-
gram development in child and 
adolescent psychiatry. 
Weinstein expresses gratitude 
to those who gave her roots, her 
family and mentors. Growing 
up in Hartford, Conn., as the 
oldest of five, hers was a child-
hood of stories. “I used to lis-
ten to stories about my Jewish 
grandparents immigrating to 
the U.S. from Poland to escape 
pogroms and find freedom,” 
she recalled. “They came here 
with little, starting with my 
grandfather having a pushcart, 
to establishing a grocery store 
where people would congregate 
to ask his advice and share their 
stories. I listened to family sto-
ries of courage and resilience, of 
my dad’s bravery at Normandy 
on D-Day, and about my mom’s 
dedication to her family.”
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Weinstein is grateful 
for the foundation and 
stability her family 
provided, and she has 
striven to build the 
same for her own son, 
now 23. “It’s such a gift 
to see the excitement 
in children when they 
accomplish their goals,” 
she said.
education, and advocacy. She is a 
Distinguished Life Fellow of the 
American Psychiatric Association 
and the American Academy of 
Child and Adolescent Psychiatry; 
received a Lifetime Achievement 
Award from the New England 
Council of Child and Adolescent 
Psychiatry (NECCAP); and has 
served several terms as NECCAP 
president. Over 30 years, she has 
organized 170 psychiatric confer-
ences and taught thousands of 
Harvard Medical School students 
and psychiatric residents.
Looking forward, Weinstein 
is concerned about a critical 
shortage of child and adolescent 
some female classmates being 
told they were “taking the place 
that a man could have, that they 
would have children and stop 
practicing medicine.”
Weinstein challenged 
biases through evidence-based 
research—her approach since her 
first science fair project when she 
was 12. In college, she disputed 
the belief that women should 
not hold key political positions 
because of “raging hormonal 
influences” by writing a thesis 
examining emotions throughout 
the menstrual cycle. In medical 
school, her thesis centered on 
gender differences in depression. 
“It was an exciting time,” she said. 
“The whole field of gender and 
female development was being 
studied, researched, and radi-
cally revised to the good.” 
Weinstein volunteered at 
pregnancy counseling services 
in Boston and often accompa-
nied women seeking legal abor-
tions to clinics in New York, 
sometimes crossing picket lines. 
“I grew up seeing how important 
it is for a woman’s dignity and 
self-actualization to have the 
right to make choices about her 
own body,” she said.
Weinstein also recognized the 
connections between environ-
ment, biology, psychology, and 
development, and deepened her 
appreciation of knowing and 
treating the “whole person” at 
Yale School of Medicine. “Yale 
was renowned for excellence and 
an innovative, far-reaching cur-
riculum, especially in psychiatry,” 
she said. “Outstanding faculty 
taught us a humanistic, compas-
sionate approach to the doctor-
patient relationship.”
Weinstein brought the multi-
disciplinary philosophy to her 
adult residency and child and 
adolescent residency at McLean 
Hospital in Belmont, Mass., and 
to the Boston Psychoanalytic 
Society and Institute (BPSI). She 
ultimately focused on work with 
children, adolescents, adults, 
and families, both in her private 
practice in Lexington, Mass., 
and in paying forward her fam-
ily’s educational legacy through 
teaching at McLean and Harvard 
Medical School.
The Massachusetts Psychiatric 
Society award is the latest in 
Weinstein’s encyclopedic-
résumé, which includes honors 

















PA Online students visit 
Yale twice during their 
didactic year to get 
“hands-on” experience 
with professors and 
interact with each other. 
Yale Medicine Magazine 
popped in to see how a 
recent visit went, and 
what the students 
learned from their im-
mersion exercise.
For more on their talk,  
visit ymm.yale.edu/ 
immersion
psychiatrists. “Nearly one in 
five U.S. children has a mental, 
emotional, or behavioral dis-
order within a given year, and 
only about 20 percent receive 
care from a specialized mental 
health care provider,” she said. 
“We need more pediatric psy-
chiatrists to meet these needs. 
It’s a dynamic and rewarding 
field. With significant advances 
in research and treatments, 
psychiatrists can partner with 
families and colleagues to advo-
cate, help children build on their 
strengths, and create solid foun-
dations for the future.”
Weinstein finds her work 
hopeful and embraces the 
optimism of change and pos-
sibilities. “Much of the power of 
intervention, through educa-
tion, connection, social action, 
and multimodal evidence-based 
treatments is in being able to 
rewrite your narrative,” she said. 
“You can see your past through 
a different lens and rewrite your 
narrative for the future, know-
ing that the end of the story has 
not yet been written.”
As with her family, it all 
comes back to stories. 
—Lauren Johnson 
»
A study in innovation: 
Reinventing substance 
use disorder intervention
The fields of education and psy-
chiatry value researchers who 
are willing to combine fresh ideas 
with traditional solutions. That 
kind of open-minded approach 
led Ayana Jordan, MD, PhD, to 
an epiphany as she sought a 
better way to help poor people 
struggling with drug addiction. 
Though it happened in church, 
her epiphany was not religious 
in nature. Jordan realized that 
the influence and support of 
the African Methodist Episcopal 
Zion Church could provide 
the transformative experience 
people needed when they didn’t 
have much trust in health care. 
Through her positions as assis-
tant professor of psychiatry and 
director of the Yale Global Mental 
Health Program, she was able to 
draw on colleagues and church 
leaders to break new ground in 
addiction interventions.
Raised in Pittsburgh, Jordan 
began her award-studded 
academic life with an under-
graduate degree in biology from 
Hampton University in Virginia, 
a school steeped in Black his-
tory and culture with a progres-
sive mandate. She embarked on 
an MS in pathology at Albert 
Einstein College of Medicine  
of Yeshiva University in the 
Bronx, then stayed on for an  
MD/PhD program.
Completing the combined 
degree program is a rare accom-
plishment for any student. The 
number of Black women who 
achieve it is miniscule. “I planned 
to go into internal medicine and 
infectious disease,” she said since 
she earned her PhD in immuno-
pathology. But during the pro-
gram, she did clinical work in 
psychiatry in the South Bronx.  
“I had never seen that level of 
poverty in the U.S. It really struck 
me,” she said. This experience 
changed the trajectory of her 
career. “I realized I could make a 
bigger impact in the underserved 
and marginalized communities. 
There is such a big mistrust in 
those communities around men-
tal health and mental illness.”  
The existing interventions weren’t 
working, and she felt compelled 
to find a solution.
“To improve outcomes for 
marginalized populations, we 
need to involve them from 
research to clinical interaction— 
every step of the way,” Jordan 
explained. This kind of com-
munity-based participatory 
research wasn’t an option in most 
residency programs. At Yale, she 
found an environment that sup-
ported her vision to integrate the 
cultural and religious aspects of 
people’s lives while also address-
ing the disparities that can hold 
them back from improved mental 
health. Jordan also discovered a 
community in need: According 
to the National Institutes of 
Health, Connecticut is among the 
top 10 states for overdose deaths 
from opioid abuse. She arrived in 
New Haven in 2011, as the rate of 
opioid deaths in the state started 
to climb dramatically. 
During her residency, she 
served as program-wide chief 
resident in psychiatry; com-
pleted a fellowship in addiction 
psychiatry; amassed a dozen 
awards, including the Resident 
Recognition Award from the 
American Psychiatric Association 
(APA); and found an innovative 
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support to address such factors 
that might compromise success  
as issues with housing, jobs,  
and transportation. 
When the program launched, 
hundreds of people came. The 
success led to further funding for 
another year. Jordan and Bellamy 
are now expanding the program 
by designing a version for the 
Latinx community. “The next 
challenge is preparing a large 
randomized controlled trial to 
determine if partnering with the 
faith organizations works better 
than traditional substance use 
clinics,” Jordan said.
While Jordan has won many 
awards and accolades, one of  
her favorites was bestowed at 
Yale’s commencement last June: 
the Faculty Diversity Award.  
“I wanted to recruit residents and 
faculty that are reflective of the 
population, to make sure all kinds 
of people are at the table—race, 
gender, point of view, where we 
trained, and more. You can’t be an 
excellent physician unless you are 
aware of the cultural identity that 
patients bring into the room and 
take that into consideration in the 
treatment plan. Yale psychiatry 
is starting to reap the rewards of 
being focused on inclusion.”
Jordan said she hopes to help 
everyone find a path to recovery, 
regardless of past failures. “My 
ultimate dream is to open up a 
substance abuse wellness center 
that not only deals with the bio-
logical aspects of substance use, 
but equally addresses the social 
determinants of health,” she said.
—Elena Rover
approach to community inter-
vention. When Jordan arrived 
in New Haven, one of her top 
personal priorities was to find 
a Black church. She joined 
Varick Memorial AME Zion 
Church, which has a long tradi-
tion of participation in studies 
at Yale. Knowing that the Black 
church had been instrumental 
in changing how people thought 
about HIV, Jordan realized 
the church community could 
help with another stigmatized 
epidemic: mental illness, spe-
cifically substance use disorder. 
She approached the pastors to 
propose a pilot of a community-
based treatment program within 
the church. 
While it may sound a bit like 
12-step meetings held in church 
halls, which Jordan acknowledges 
can help many people, this pro-
gram is quite different. “Here we 
are focused on being Black, being 
spiritual, [and] the church itself 
is involved in the care,” she said. 
“It’s not about bringing people to 
Jesus, and participants are often 
not part of the congregation,” she 
explained. “It’s about a safe place 
where people can get help.” The 
pilot program was held in Dixwell 
Avenue Congregational United 
Church of Christ. It included 
evidence-based computerized 
cognitive behavioral therapy, and 
received an overwhelmingly posi-
tive response.
At the same time, Jordan 
hoped to bring a faith-based ini-
tiative to members of the Black 
community with opioid use dis-
orders throughout the state. That 
led to a collaboration with Chyrell 
Bellamy, MSW, PhD, associate 
professor of psychiatry, on a pro-
gram called Imani Breakthrough 
(imani means “faith” in Swahili). 
With input from peer facilitators 
and church leaders, they added 
the traditions and values of the 
church to a curriculum based 
on the Citizens-Community 
Enhancement Project, an inter-
vention shown to be effective  
for people with serious mental  
illness that includes substance  
use disorders. 
The foundation of Imani 
Breakthrough is the 5Rs model 
from the Citizens’ Project, cre-
ated by Michael Rowe, PhD, 
professor of psychiatry, and his 
colleagues. The model empha-
sizes the “rights, responsibilities, 
roles, resources, and relation-
ships” of community members. 
Imani Breakthrough also incor-
porated a support system that 
encompasses spiritual, social, 
financial, emotional, environ-
mental, intellectual, physical 
and occupational aspects of 
life—the “Eight Dimensions of 
Wellness,” as outlined by the 
Substance Abuse and Mental 
Health Services Administration 
of the U.S. Department of Health 
and Human Services.
Imani Breakthrough aims to 
help people gain independence 
without relying on perennial 
attendance at meetings. The pro-
gram involves 12 two-hour weekly 
meetings and refers patients to 
medication-assisted treatment and 
wellness counseling when appro-
priate. It also includes one-on-one 
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   The biochemical  
 basis of human mood
Statistics generally  
show an upward trend 
in rates of depression, 
anxiety, and addic-
tion. Are we dealing 
with an actual increase 
or just talking about 
mental health more 
openly? There is a lot 
of activity in the sphere 
of public mental health. 
First, the numbers of 
people diagnosed with 
anxiety and depression 
are going up. Second, the 
rate of serious conse-
quences of inadequately 
treated mental illness, 
like disability and sui-
cide, are going up. Third, 
we have a very serious 
shortage of psychiatrists 
and psychologists. We’ve 
tolerated this shortage 
because society has tra-
ditionally viewed mental 
illness as something that 
can be treated if there are 
resources available, a sort 
of add-on to health care. 
Many people, includ-
ing myself, believe that 
we need a new model 
whereby mental health 
is a core element of pri-
mary medical care. In 
our society, more than 
two-thirds of people are 
routinely screened for 
various forms of cancer—
but more than two-thirds 
of people are not screened 
for mental illness or 




DURING HIS FIRST SUMMER IN COLLEGE, John Krystal, 
MD ’84, HS ’88, chair of Yale’s psychiatry department, 
traveled from the University of Chicago to help patients at 
a methadone-dispensing addiction clinic in Boston. In a 
biochemistry class that autumn, he learned about the dis-
covery that the body makes opioid-like molecules called 
endorphins that act via the same receptors in the brain as 
drugs like heroin and methadone. An idea clicked. “That 
suggested to me that the problem of addiction might have a 
scientific underpinning,” Krystal, the Robert L. McNeil, Jr. 
Professor of Translational Research, professor of psychia-
try, and of neuroscience, said, “and that the complexity 
and unpredictability of clinical psychiatry work could be 
grounded in discoverable, scientific principles about brain–
behavior relationships.” 
{ To nominate a subject for Q&A, contactYale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510, or email ymm@yale.edu.
The direct link between bio-
logical processes in the brain 
and a person’s behavior is widely 
accepted today, but it seemed 
radical three decades ago. When 
Krystal was an undergraduate, 
the late Yale psychiatry profes-
sor Daniel X. Freedman, MD, 
directed him toward the lab of 
Richard J. Miller, PhD, a pio-
neer in opiate-receptor research. 
Since then, Krystal has built a 
career bridging basic science 
with clinical understandings of 
depression, alcoholism, post-
traumatic stress disorder (PTSD), 
and schizophrenia. 
In this Yale Medicine 
Magazine interview, Krystal dis-
cussed a deep and wide range of 
topics from across his roles, which 
also include chief of psychiatry at 
Yale New Haven Hospital, editor  
of the journal Biological 
Psychiatry, director of clinical 
neuroscience at the Department 
of Veterans Affairs National 
Center for PTSD, and numerous 
advisory responsibilities.






is progressing rapidly. 
Why might the public still 
think of mental illness as 
shrouded in mystery?  
The symptoms of mental ill-
ness—including changes in 
mood, patterns of thought, 
or behavior—can be con-
fusing or even frightening. 
Providing a scientific foun-
dation for understanding 
these symptoms that guides 
the processes of diagnosis 
and treatment could have 
profound implications for 
how society thinks about 
these problems.
What changes do we 
need in how mental ill-
ness is treated? I think 
we need a new model. As 
a society and as a medi-
cal specialty, we need to 
take responsibility for 
the outcomes of mental-
illness treatment. To do 
that, we have to measure 
the outcomes of treatment 
and use this information 
to inform clinical prac-
tice. The current model 
has some parallels to the 
way we treat infection, in 
that the most commonly 
used treatments are not 
always the most effective. 
We save the most effective 
treatments for “treatment-
resistant” symptoms. But 
that is not what we do in 
cancer. There, we initiate 
What is a dream you 
have for the future of 
psychiatry? We are work-
ing toward an era of preci-
sion psychiatry. By that 
I mean having tests that 
diagnose risk or disease 
processes for individu-
als and that enable us to 
engage specific prevention 
and treatment interven-
tions. We envy cardiology, 
where one can diagnose 
and treat hypertension 
and thereby prevent myo-
cardial infarction. We may 
be able to use genetics 
to identify people at risk 
for problems, but then 
we also may need to deal 
with the societal issues 
that increase risk, such 
as childhood exposure to 
violence, abuse, neglect, 
and maternal depression 
and addiction. Future 
treatments may involve 
gene- or cell-based thera-
pies or procedures only 
imaginable on shows like 
Star Trek, where a scan 
is performed that tells us 
how to stimulate the brain 
to alleviate symptoms. 
Who knows what will 
come? Cure is not a word 
that we use in psychiatry, 
but that too is simply a 
reflection of the limits of 
our knowledge in compa-
rison to the enormity of 
the challenge of under-
standing the brain.
definitive treatment as 
soon as the problem is 
diagnosed. We need to 
offer more care like that. 
If we diagnose depression, 
we need to make sure you 
get a comprehensive array 
of services. Also, when 
people fail to respond to 
established cancer treat-
ments, a high percentage 
of patients will enroll in  
a research study to test 
new treatments. That  
is not the way we deal  
with mental illness or 
addiction, where only a 
small fraction of patients 
participate in research.
Which mental health 
trend disturbs you most 
today, and which trend 
gives you the most 
energy? The trends that 
disturb me most also 
energize me the most: the 
increase in opiate-related 
deaths and the increase 
in suicide. Psychiatry is 
unique in that mortality 
from psychiatric illness 
is increasing, whereas 
mortality from practically 
every other diagnosis is 
decreasing. Cancer mor-
tality, diabetes mortal-
ity,  and heart-disease 
mortality are going down. 
But suicide and addiction-
related deaths are going up. 
We have to do things dif-
ferently—and not just as a 
department or health care 


















  A stimulating  
 book on hormones
   By Cathy Shufro
In 1902, two English physi-
ologists, William Bayliss and 
Ernest Starling, undertook 
gruesome experiments on a 
dog to prove that hormones 
are essential to canine diges-
tion. As Randi Hutter Epstein, 
MD ’90, MPH, recounts in her 
new book, those experiments 
confirmed that the glands 
scattered in the body—whether 
canine or human—have 
something in common: they 
produce hormones. The field of 
endocrinology was born.
The next year, animal 
rights activists watched 
Bayliss and Starling cut into 
a dog’s throat at a demo for 
medical students. Epstein tells 
how anti-vivisectionists pro-
tested the dog’s treatment and 
erected a statue of a canine in 
South London that read, “In 
Memory of the Brown Terrier 
Dog Done to Death.” Medical 
students, in turn, mobbed the 
streets, shouting, “Down with 
the Brown Dog!” 
This interweaving of 
science and story is char-
acteristic of Aroused: The 
History of Hormones and 
How They Control Just about 
Everything. While tracing 
the history of endocrinology, 
Epstein includes accounts of 
hucksters, eugenicists, and 
murderers. She writes about 
how hormones affect those 
going through menopause, 
are intersex, are gender 
transitioning, or experienc-
ing fluctuations in weight.
Epstein hopes these tales 
will attract a broad audi-
ence. “I’m trying to hook 
in the reader who would 
say, ‘I never thought I’d read 
a book about the history of 
medicine—and I don’t know a 
thing about chemistry—but I 
really understand it, because 
the stories are so great.’ ”
One such story: In 
1960, when a doctor pre-
dicted that 7-year-old Jeff 
Balaban “might never make 
it past four feet,” his mother 
took action: she recruited 
pathologists to donate 156 
human pituitary glands from 
cadavers each year to sup-
ply growth hormone for Jeff. 
As Epstein writes, “It would 
take a graveyard of bodies 
to make him grow.” Balaban 
proved lucky; since 1985, 
more than 226 other people 
treated with glands obtained 
from cadavers have died 
from iatrogenic Creutzfeldt-
Jakob Disease (iCJD) which 
is transmitted by prion-con-
taminated growth hormone. 
Physicians now use synthetic 
growth hormone.
One of Epstein’s favorite 
stories is that of Rosalyn 
Sussman Yalow. Born in 1921 
to Jewish immigrants, she 
found a spot in physics grad-
uate school only after male 
students left for the mili-
tary. “They had to go to war 
so I could get a PhD,” Yalow 
declared. In 1959, she and 
colleague Solomon Berson 
developed a way to measure 
hormones in the body. The 
radioimmunoassay (RIA) 
detects hormones down to 
one-billionth of a gram per 
milliliter of blood. As Epstein 
writes, “That’s like being able 
to measure the extra water in 
a swimming pool after one 
swimmer sheds a tear.” RIA 
can detect various biological 
substances and is fundamen-
tal to fertility treatments and 
detecting HIV. Pediatricians 
have used RIA to virtu-
ally eliminate the thyroid 
deficit that causes congenital 
hypothyroidism; they rou-
tinely prick the heels of new-
borns to spot the deficiency. 
Epstein describes the 
barriers that Yalow had 
to breach. She ignored a 
rule at the Bronx Veterans 
Administration Hospital 
requiring pregnant women 
to resign in the fifth month. 
Journals repeatedly rejected 
her first groundbreaking 
article. In an interview, 
Epstein described Yalow’s 
advice to a group of third-
graders: “ ‘Hold onto all your 
rejection letters, because 
you can display them dur-
ing your Nobel awards cer-
emony.’ Which Yalow did.” 
She received the Nobel Prize 
in physiology or medicine in 
1977 for inaugurating “a new 
era of endocrinology.”
Epstein said that during 
five years of researching and 
writing the book, she saw a 
pattern in how people have 
responded to discoveries 
about hormones. “Here are 
these chemicals that seem to 
control us, and we ask, ‘How 
can we control them?’ That’s 
human nature. We learn 
something about health or 
wellness or disease, and then 

























{Send notices of new books toYale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510, or email ymm@yale.edu.
book review
T H E AUC T ION I N C A F É M E D on the evening of December 6, 2018, was the 26th in an annual series 
that has raised money for New Haven organizations that provide services to those in need. This 
year’s auction raised $15,306 for four of the 28 organizations that applied for funding: Cornell Scott-
Hill Health Center; Integrated Refugee and Immigrant Services (IRIS); Love Fed New Haven, which 
makes healthy and affordable food available through community gardens; and Youth Continuum, 
which serves homeless youth in the city.
Noting the auction’s long-standing tradition, organizer and second-year student Melanie Zheng 
said, “It’s a great event because it allows us to help the community we were meant to serve.”
The auction began at 5 p.m. with music from the Railboys, a jazz ensemble made up of medical 
students. At 6 p.m., William Stewart, PhD, who has taught anatomy to generations of Yale medical 
students, took to the lectern as the first of several auctioneers. He would, he said, dispense with the 
kindness and understanding he displays in the anatomy lab. “My one job is to get into your wallets, 
so I am not going to show any mercy at all.”
As in past years, Stewart offered one of his signature bow ties, provoking the traditional rivalry 
between students in the Physician Associate Program and medical students. The PA students won 
with a bid of $2,080.
—John Curtis
 Going once,  
going twice
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